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Introduction  
 
The relationship between abnormal invasive placenta (AIP), preterm 
delivery and brain injury. 
 
Abnormal invasive placentation (AIP) is a potentially life-threatening complication of 
pregnancy characterized by an abnormal adherence of the placenta to the uterine wall 
(1). Its clinical consequence is failure of placental separation leading to massive 
postpartum haemorrhage with a significant increase in maternal morbidity and 
mortality. The reported incidence of abnormal placentation is highly variable, ranging 
from 1:93 000 to 1:111 pregnancies (2). A deficit in the uterine wall thickness due to a 
scarred uterus or an abnormal placentation site in the lower segment is a major risk 
factor (3). An increasing incidence of AIP has been demonstrated to be related to 
higher rates of cesarean section (CS). Therefore, populations with a high CS rate, 
such as in southern Italy, are expected to have an increased incidence of AIP (4, 5). 
While obstetricians agree that a planned delivery with a multidisciplinary team is the 
best management option to optimize maternal outcomes, there is little evidence to 
guide the timing of delivery for previa-accreta patients. Choosing the timing of delivery 
is critical in terms of limiting both maternal and neonatal risk. Several studies have 
suggested the benefits of planned delivery in the reduction of maternal morbidity. An 
early delivery can be beneficial as it allows to arrange a multidisciplinary team and to 
avoid an emergency delivery because of bleeding or labour. However, a scheduled 
delivery often means delivery of a premature infant, and all the risks related to 
iatrogenic prematurity must be taken into account (6-8). 
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Placenta previa and AIP represent the second most common cause for indicated 
preterm delivery, accounting for 5.6-8.7% of iatrogenic preterm deliveries (9). Preterm 
delivery before 37 weeks represents a major burden worldwide, with 15 million preterm 
births per year. Preterm birth is associated with many specific acute complications of 
immaturity. In almost all high- and middle-income countries, preterm birth is the 
leading cause of child deaths. In addition to its contribution to mortality, preterm birth 
can have lifelong effects on neurodevelopment, with increased risks of cerebral palsy, 
impaired learning, and mental disorders (10). Of 15 million (12.3–18.2 million) preterm 
births per year, 13.0 million (12.7–14.3 million) are estimated to survive the neonatal 
period. Among them, 0.9 million (uncertainty range: 0.8–1.1 millions) of these 
survivors will suffer long-term neurodevelopmental impairment with 345,000 
moderately or severely affected (11).  
 
Preterm brain injury results from developmental vulnerability given that the brain 
weighs only 65% of its full-term weight at 34 weeks and glial cell migration continues 
to 36 weeks. Gyral and sulcal development is still incomplete late preterm. The cortical 
volume in the late preterm infant is only 53% of the term volume, with approximately 
half the volume to be obtained in the last 6 weeks before 40 weeks. Brain insults in 
the late preterm brain can also alter the trajectory of specific programs in neuronal and 
glial development, as they do in the very premature brain, thereby contributing to the 
neurological disabilities of the survivors (12).  
 
Ideally we would deliver patients with AIP at the gestational age at which lowest 
morbidity for the mother coincides with lowest morbidity for the infant. As the second 
leading cause of iatrogenic prematurity, during this PhD programme research has 
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been focused on the epidemiology, diagnosis, and management of AIP, trying to 
provide more evidence to restrict the earliest planned AIP deliveries to situations with 
demonstrated benefit. 
 
PhD research: objectives and sessions 
 
The aim of this research project was to exploit the epidemiology, diagnosis and 
management of abnormally invasive placenta: 
 
• The Session A was developed in the years before the beginning of the PhD and 
represents a starting point for the line of research developed afterwards. This 
is a retrospective study investigating the epidemiology of AIP in terms of 
incidence and risk factors in our population in the last 3 decades. The results 
of the study have been published in a peer reviewed journal (5). 
 
• The Session B has been developed in the first two years of research and it 
encompasses two studies investigating the aspects of the diagnosis of the AIP. 
The first one is a multicentre study including data from 11 hospitals in Italy 
which has been recently accepted for publication on Gynecologic and Obstetric 
Investigation (manuscript No.: 201803046). The second study is a systematic 
review and meta-analysis on the predictive accuracy of different Color Doppler 
signs for the diagnosis of AIP. This study has been submitted for publication 
and is currently under peer review. 
 
• The Session C has been developed in the third year of research and it deals 
 9 
with the problem of the management of AIP. Two studies are included in this 
section. The first one is the result of the international collaboration with the 
International Society for Abnormally Invasive Placenta (IS-AIP), of which our 
centre is part of. This study represents the first ever published evidence based 
guidelines for the management of IS-AIP and it is currently under peer review. 
The second study is a prospective research conducted in our centre, dealing 
with the problem of the gestational age at delivery in women with AIP, trying to 
optimize maternal outcomes and to reduce unnecessary neonatal prematurity. 
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Section A – Epidemiology 
 
Placenta accreta: incidence and risk factors in an area with a particularly 
high rate of cesarean section. 
 
Morlando M. et al. Placenta accreta: incidence and risk factors in an area with a 
particularly high rate of cesarean section. Acta Obstet Gynecol Scand 2013; 92:457–
460. 
 
Background 
Placenta accreta (PA) is a potentially life-threatening complication of pregnancy 
characterized by an abnormal adherence of the placenta to the uterine wall (1), 
secondary to an absence or deficiency of Nitabuch’s layer of the decidua (2). The term 
abnormal placentation is colloquially used for the three known variants of placenta 
accreta, increta or percreta (1). The clinical consequence of abnormal placentation is 
failure of placental separation leading to massive postpartum hemorrhage with a 
significant increase in maternal morbidity and mortality (1). The reported incidence of 
abnormal placentation is highly variable, ranging from 1:93 000 to 1:111 pregnancies 
(4). A deficit in the uterine wall thickness due to a scarred 
uterus or an abnormal placentation site in the lower segment is a major risk factor (5). 
An increasing incidence of abnormal placentation has been considered most likely 
related to much higher rates of cesarean section (CS) (5,6). Countries with a high CS 
rate, such as Italy (7), are expected to have an increased incidence. 
We have investigated the changes in the incidence of PA and associated risk factors 
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along four decades from 1970s in a tertiary south Italian center. 
 
Material and Methods  
A retrospective study of medical charts to identify all patients with PA was conducted. 
To evaluate incidence variation from the 1970s to 2000s we analysed all cases of PA 
(increta and percreta are included as they could often not be safely distinguished from 
accreta) in a sample triennium for each decade. Printed copies of the clinical notes 
were available starting from the 1976. The first triennium sample was considered from 
January 1976 to December 1978; then in any 10-year interval, an analogue three-year 
period at was studied, i.e. 1986–1988, 1996– 1998 and 2006–2008. 
Placenta accreta was defined as any abnormal adherence of the placenta to the 
uterine wall (“accretism”) (1). Diagnosis had to be based on clinical and histological 
findings (4,6,8), using (i) histopathologic confirmation on a hysterectomy specimen by 
absence of the intervening layer of decidua, Nitabuch’s layer (2), between placenta 
and myometrium, (ii) incomplete manual removal of the placenta despite active 
management of the third stage of labor or (iii) heavy continued bleeding from the 
implantation site of a well-contracted uterus after difficult removal of the placenta 
during CS. 
Variables included in the analysis were: maternal age, parity, previous abortions and 
curettages, CS, any other uterine surgery, placenta previa according to third trimester 
ultrasound examination, in vitro fertilization, uterine artery embolization in a previous 
pregnancy, female new- born gender (3–5,8,9). Risk factors for PA were analysed 
using the chi-squared test for categorical variables, and an ANOVA test for continuous 
variables. P-values <0.05 were considered significant. The institutional ethical 
committee approved the study. 
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Results 
During the four triennia there were 30 491 deliveries at our center, from which 50 cases 
of PA were diagnosed (Table 1). The incidence of PA grew from 0.12% (1/833) during 
1976–1978, to 0.31% (1/322). At the same time, CS rate went from 17 to 64% during 
the last triennium (Figure 1). 
Of the PA cases, nine women delivered vaginally. Among them, seven had blood 
products transfusions, five had dilatation and curettage, one of whom required a 
hysterectomy. Among women delivering vaginally, there were four hysterectomies due 
to uncontrollable bleeding. 
Forty-one women were delivered by CS: 23 had trans- fusions, three were successfully 
treated with curettage and 26 required a hysterectomy. One woman had hypogastric 
artery ligation as adjuvant treatment to reduce hemorrhage during the cesarean 
hysterectomy. Twelve women were successfully treated by uterine packing only. 
There were 30 hysterectomies. In nine cases (30%) the histology confirmed the PA 
(four increta, five percreta); in 14 the histological result was negative (46%). Seven of 
the early cases from the first triennia could not be reviewed due to lost or destroyed 
documents. There were 13 primiparous women, three of whom delivered vaginally, 
while CS was carried out in 10 for different obstetrical indications. There were no cases 
of maternal death. 
Table 1 shows risk factors in the four decades. No significant differences were seen 
for any of the most com- mon variables, except previous CS (p < 0.05). 
 
Discussion 
This observational study shows an increasing incidence of PA over time from the 
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1970s to the 2000s. Risk factors did not change to any significant degree over the last 
four decades except for CS. 
Due to the absence of 23% of histology reports, the diagnosis was based mostly on 
clinical criteria. The literature is controversial on the sensitivity and specificity of the 
clinical criteria compared with histological diagnosis (3,4,8,10). The exclusion of the 
cases with negative histological examination may underestimate the real incidence 
(3). The absence of indicative histological features in cases of clinically suspected PA 
does not exclude the diagnosis (10). We excluded all cases of simple retained 
placenta. Most of the cases were discovered at CS and a senior consultant was always 
involved in the management. It is therefore unlikely that the PA false-positive rate 
would have influenced the incidence rate, even if some cases of retained placenta 
were considered PA. 
Other authors have reported rising rates of PA in the last decades (4,6). To the best 
of our knowledge, this is the longest observed period reporting the last 40 years of PA 
frequency variance. The incidence in the last decade is comparable with more recently 
published studies (0.01– 0.9%) (4,6,8). 
The high CS rate was the only characteristic significantly different from 1970s to 2000s 
(from 18 to 63%). The possible explanation for this has been investigated previously. 
The human embryo develops in a relatively hypoxic environment, and data from in 
vitro studies suggests that oxygen tension determines whether cytotrophoblasts 
proliferate or invade, thereby regulating placental growth (11). Embryos may 
preferentially implant into areas of uterine scarring because of the lower 
vascularization and lower oxygen tension. 
Our study has several limitations, including the retrospective evaluation of case notes 
where reporting was not consistent with regard to histology and data entry, affecting 
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the reliability of the clinical diagnosis. Moreover, electronic databases were not 
available from the 1970s and 1980s and this leads us to assume that a considerable 
amount of missing data cannot be recovered to evaluate the real incidence of PA in 
the last 40 years. Whether the four sample triennia are representative of the entire 
decade cannot be verified. 
Considering the inevitable worldwide increasing rate of CS, further efforts should be 
spent on screening and management to prevent the consequent rise in maternal 
morbidity and mortality due to PA (6). 
 
Acknowledgements 
The authors would like to thank Daniela Russo, MD for her research work on 
anatomopathology records. 
  
 17 
References 
1. Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet 
Gynecol. 2006;107:927–41. 
2. Benirschke KKP, Kaufmann P. Pathology of the human placenta, 4th edn. New 
York: Springer, 2000. 
3. Miller DA, Chollet JA, Murphy TM. Clinical risk factors for placenta previa-placenta 
accreta. Am J Obstet Gynecol. 1997;177:210–4. 
4. Gielchinsky Y, Rojansky W, Fasouliotis SJ, Ezra Y. Placenta accreta: summary of 
10 years: a survey of 310 cases. Placenta 2002;23:210–4. 
5. Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, et al. Maternal 
morbidity associated with multiple repeat caesarean deliveries. Obstet Gynecol. 
2006;107:1226–32. 
6. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. 
Am J Obstet Gynecol. 2005;192:1458–61. 
7. Betr an AP, Merialdi M, Lauer JA, Bing-Shun W, Thomas J, Van Look P, et al. Rates 
of caesarean section: analysis of global, regional and national estimates. Paediatr 
Perinat Epidemiol. 2007;21:98–113. 
8. Hung TH, Shau WY, Hsiech CC, Chiu TH, Hsu JJ, Hsieh TT. Risk factors for 
placenta accreta. Obstet Gynecol. 1999;93:545–50. 
 
  
 18 
Figure 1 
 
 
 
 
 
 
 
 
 
Table 1 
  
 19 
Section B – Diagnosis (I) 
 
Clinical and ultrasound predictors of placenta accreta in pregnant women 
with antepartum diagnosis of placenta previa: a multicenter study. 
 
De Vita et al. Clinical and ultrasound predictors of placenta accreta in pregnant women 
with antepartum diagnosis of placenta previa: a multicenter study. Accepted on 
Gynecologic and Obstetric Investigation (manuscript No.: 201803046). 
 
Background  
Abnormally invasive placenta (AIP) defines a placenta that doesn’t separate 
spontaneously at delivery and its removal causes abnormally high blood loss; AIP 
encompasses the histopathological diagnosis of placenta accreta, placenta increta 
and placenta percreta [1]. Placenta accreta is more common in women with a history 
of multiple caesarean section and the presence of a placenta previa than women 
without these risk factors. Placenta accreta increases the risk of major complications, 
such as fetal loss [2], bleeding [3], and hysterectomy [4]. Due to an increasing 
proportion of caesarean deliveries [5], the risk of placenta accreta has increased in 
the last two decades [6].  Silver et al. 2006 [7] reported that placenta accreta was 
present in 15 (0.24%), 49 (0.31%), 36 (0.57%), 31 (2.13%), 6 (2.33%), and 6 (6.74%) 
women undergoing their first, second, third, fourth, fifth, and sixth or more cesarean 
deliveries, respectively. AIP should be investigated in women with previous uterine 
surgery [8-9] and women with placenta previa [8]. Several ultrasound features have 
been suggested for diagnosis of placenta accreta such as: irregularly shaped placental 
lacunae (vascular spaces), thinning of the myometrium overlying the placenta, loss of 
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the retroplacental “clear space”, protrusion of the placenta into the bladder, increased 
vascularity of the uterine serosa/bladder interface, and turbulent blood flow through 
the lacunae on Doppler ultrasonography [10]. Magnetic resonance imaging (MRI), 
even if used widely in cases of suspected AIP, has yet to be showed to clearly to 
improve pregnancy outcome. Furthermore, diagnostic accuracy depends on the 
training and level of experience of the physician, irrespective of the imaging technique 
[1]. Ultrasound is the primary tool to diagnose AIP in women at risk, such as those with 
placenta previa and a prior cesarean section, whereas prenatal magnetic resonance 
imaging (MRI) is usually reserved for cases with inconclusive ultrasound assessment 
[11].  In fact, ultrasound had an overall good diagnostic accuracy in identifying the 
depth of placental invasion with sensitivities of 90.6%, 93.0%, 89.5%, and 81.2% for 
placenta accreta, increta, accreta/increta, and percreta, respectively [12]. 
Here we aimed to assess whether ultrasonography might help identify predictors of 
placenta accreta and hysterectomy in a large group of pregnant women in Italy with 
antepartum diagnosis of placenta previa. 
 
Material and methods 
 
Participants and clinical characteristics  
             A cross-sectional study was performed in eleven centres placed in Italy. 
Caucasian women with an ultrasound diagnosis of placenta previa in pregnancy 
delivering at the participating centres were recruited between May 2015 and April 
2016.  Placenta previa was classified based on the relationship between the placental 
margin and the internal os. Antepartum diagnosis of placenta previa at ultrasound scan 
was defined when the placenta covers the internal os and marginal placenta, when it 
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is sonographically measured < 20 mm of the internal os. (Fig. 1). [13]. All women 
underwent a transabdominal ultrasound scan followed by transvaginal scan and 
placental evaluation performed from 25+0 weeks to 40 weeks of gestational age, 
investigating the following criteria [2]: (1) irregularly shaped placental lacunae 
(vascular spaces), (2) thinning of the myometrium overlying the placenta with a cut-off 
of 1 mm:, (3) loss of the retroplacental “clear space”, (4) protrusion of the placenta into 
the bladder, (5) increased vascularity of the uterine serosa/bladder interface, (6) and 
turbulent blood flow through the lacunae on Doppler ultrasonography (Fig. 2). Placenta 
accreta was defined as trophoblastic attachment to the myometrium without 
intervening decidua. If the trophoblast invades the myometrium, it is termed placenta 
increta, and if it invades through the myometrium beyond the serosa and into 
surrounding structures such as the bladder, it is termed a percreta. Often the term 
placenta accreta is used to refer to the entire spectrum of conditions including accreta, 
increta, and percreta as well as to cases of clinically apparent morbidly adherent 
placenta. In this study, the term “placenta accreta” refers to the entire spectrum unless 
specifically noted.  AIP was established at postpartum histological evaluation. 
Placenta accreta was separated into 3 categories: placenta creta when the villi simply 
adhere to the myometrium, placenta increta (PI) when the villi invade the myometrium, 
and placenta percreta (PP) when the villi invade the full thickness of the myometrium. 
[14]. A detailed anamnesis was obtained including age, parity with number of vaginal 
deliveries and caesarean deliveries, previous myomectomies, curettages, and 
resectoscopies. The respective Ethical Committee of all participating sites approved 
the study and all patients provided written informed consent. 
 
Statistical analysis 
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Continuous variables were expressed as mean ± standard deviation and compared 
with t test, if normally distributed, and with the Mann–Whitney U test, if not normally 
distributed. Normality of variables was tested using the Kolmogorov-Smirnov test. 
Categorical variables are expressed as proportions and compared using a χ2 test. To 
determine the risk factors associated with placenta accreta and hysterectomy, logistic 
regression analyses (backward conditional) were performed including all the 
demographic, clinical and ultrasound features. Statistical analysis was performed 
using the Statistical Package for Social Sciences (SPSS 22.0) software (SPSS Inc., 
Chicago, Illinois). A P<0.05 was considered statistically significant. 
 
Results 
242 women with antepartum diagnosis of placenta previa were included. The mean 
age ± standard deviation (SD) was 33.2 ± 4.9 years, mean number of vaginal 
deliveries ± SD was 2.2 ± 1.9 and mean number of caesarean deliveries ± SD was 1.0 
± 1.1.  
Sixty-six out of 242 (27.27 %) women were nulliparous, 82/242 (33.89%) had 1 
previous cesarean section (CS), 64/242 (26.45%) had 2 previous CS, 26/242 
(10.74%) had 3 previous CS, 4/242 (1.65%) had 4 previous CS. From the anamnesis 
22/242 patients (9.09 %) had a myomectomy, 100/242 (41.32 %) had a curettage and 
5/242 (2.07 %) had a resectoscopy. Ninety-eight out of 242 (40.49 %) patients had a 
histological diagnosis of placenta accreta after the delivery. Placenta accreta was 
reported in 12/98 (12.25%), 31/98 (31,63%), 36/98 (36.73%), 19/98 (19.39%) women 
undergoing their first, second, third, and fourth cesarean deliveries, respectively. Table 
1 shows demographic, clinical and ultrasound features of women who had versus 
those who did not have a placenta accreta. Women with placenta accreta had higher 
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number of caesarean deliveries, older age compared to women with no abnormal 
placental adherence and higher probability to have at least one ultrasound feature 
among signs number 1, 2, 3, 4, 5 and 6. Higher number of caesarean deliveries (Odds 
ratio [OR]: 7.002, 95% Confidence Interval (CI): 2.119–23.135; P=0.001) and 
curettages (OR: 3.577, 95% CI: 1.160–11.037; P=0.027), older age of the woman at 
the delivery (OR: 1.116, 95% CI: 1.010–1.233; P=0.031) and lower number of vaginal 
deliveries (OR: 0.462, 95% CI: 0.265–0.804; P=0.006) were identified as risk factors 
for placenta accreta. At ultrasound, the presence of irregularly shaped placental 
lacunae (vascular spaces) (OR: 6.226, 95% CI: 2.076–10.673; P=0.008), protrusion 
of the placenta into the bladder (OR: 24.408, 95% CI: 5.359–111.179; P<0.0001), and 
turbulent blood flow through the lacunae (OR: 24.695, 95% CI: 2.278–267.711; 
P=0.008) were predictors for placenta accreta (Table 2). No other variables were 
significantly associated with the diagnosis of placenta accreta. Sixty-one out of 242 
(25.21%) patients with diagnosis of placenta accreta had hysterectomy; 17 (6.9%) had 
hysterectomy without diagnosis of placenta accreta. 
 
Discussion 
In an Italian population of 242 women with antepartum diagnosis of placenta previa. 
Ninety-eight (98/242, 40.49 %) had a histological diagnosis of placenta accreta and 
61/242 (25.21 %) patients with diagnosis of placenta accreta had a hysterectomy at 
the time of the delivery. 17/242 (67,02%) had hysterectomy without diagnosis of 
placenta accreta. A prior delivery by caesarean section was the main risk factor for 
placenta accreta. History of previous myomectomy did not increase the risk. With 
regard to ultrasound findings, we found two strong predictors of morbidly adherent 
placenta: protrusion of the placenta into the bladder and turbulent blood flow through 
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the lacunae. Our data confirm that an increasing incidence of placenta accreta is 
mainly due to the increased number of deliveries by caesarean section. In almost all 
cases, an abnormal placental invasion was at the site of the uterine scar [15]. We also 
found that older maternal age and curettages are important risk factors for placenta 
accreta, as shown previously [16]. In fact, women at most increased risk of placenta 
accreta were those who had a history of curettages, no vaginal deliveries and previous 
caesarean sections with a placenta previa overlying the uterine scar. The antepartum 
identification of women at higher risk of placenta accreta is pivotal for the reduction of 
maternal/fetal morbidity and mortality by allowing clinicians to choose the best time 
and place of birth. Multidisciplinary surgical management, neonatal intensive care, 
uterine artery embolization and an adequate number of blood products available in the 
operating room can only be achieved effectively through early detection of the 
placental pathology [10]. Ultrasonography may be used for diagnosis of abnormal 
placental adherence, but diagnostic criteria and accuracy are still under debate [17-
19]. Here, we found that having protrusion of the placenta into the bladder and 
turbulent blood flow through the lacunae would helps to identify the vast majority of 
women who had a histological diagnosis of placenta accreta at the delivery. 
Ultrasound is the primary tool to diagnose AIP in women at risk, such as those with 
placenta previa and a prior cesarean section, whereas prenatal magnetic resonance 
imaging (MRI) is usually reserved for cases with inconclusive ultrasound assessment 
[11].  On the other hand, having turbulent blood flow through the lacunae on Doppler 
ultrasonography was already found in prior studies [17-20]. Recently, a systematic 
review and meta-analysis of D’Antonio et al. [21] summarized several papers showing 
that ultrasound signs of Abnormally Invasive Placenta (AIP) are already present during 
the first trimester of pregnancy, especially before 11 weeks of gestation. Low anterior 
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implantation of the placenta/sac close to or within the scar was the most common early 
US signs suggestive of AIP, although its individual predictive accuracy was not high. 
 Rac et al. [22] constructed a receiver operating characteristic curve with the 
combination of smallest sagittal myometrial thickness, lacunae, and bridging vessels, 
in addition to number of cesarean deliveries and placental location, yielding an area 
under the curve of 0.87 (95% confidence interval, 0.80-0.95). Using logistic regression, 
a predictive equation was generated, termed the “Placenta Accreta Index.” Each 
parameter was weighted to create a 9-point scale in which a score of 0-9 provided a 
probability of invasion that ranged from 2-96%, respectively; they concluded that this 
Index may be helpful in predicting individual patient risk of morbidity adherent 
placenta. The main limitation of this study may be that the antepartum diagnosis was 
based only on ultrasound and no MRI evaluations have been performed. MRI may be 
helpful when the placenta is difficult to visualize on ultrasound due to patients’ habitus 
or to a posterior location of the placenta [23-26]. However, it has been reported no 
statistical difference in sensitivity or specificity between ultrasound and MRI [27-28]. 
Planning individual management for delivery is possible only with accurate evaluation 
of prenatal risk of accreta placentation in women presenting with a low-lying 
placenta/previa and a history of prior cesarean delivery. Ultrasound is highly sensitive 
and specific in the prenatal diagnosis of accreta placentation when performed by 
skilled operators [29]. In conclusion, women with a prior delivery by caesarean section 
have a high incidence of placenta accreta among women with antepartum diagnosis 
of placenta previa.  
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Section B – Diagnosis (II) 
 
Diagnostic accuracy of colour-Doppler ultrasound in detecting 
abnormally invasive placentation: a systematic review and meta-analysis 
 
Morlando et al. (submitted, under peer review). 
 
Background 
Abnormally invasive placentation (AIP) is a potentially life-threatening complication 
characterized by an abnormal adherence of the placenta to the uterine wall, secondary 
to a defect in the decidua basalis.1 According to the degree of placental invasion, three 
different variants of AIP can be recognized: placenta accreta, increta and percreta. 
Placenta previa and previous uterine surgery2-4 represent the main risk factors for the 
occurrence of this condition and the incidence of AIP has been shown to rise in the 
last decade most likely as the consequence of the increase in caesarean section 
rate.2,3,5 AIP is associated with the occurrence of several major complications such 
as severe maternal hemorrhage, need for blood transfusion, peri-partum hysterectomy 
and damage to adjacent organs.6  
Antenatal diagnosis of invasive placentation is associated with a reduced risk of 
maternal complications as it allows a planned management of this condition.7  
Ultrasound is usually used as the primary modality for the antenatal diagnosis of 
invasive placental disorders and is carried out especially in the second and third 
trimester of pregnancy. A recent systematic review has shown that ultrasound can 
reliably diagnose invasive placentation antenatally and that color Doppler has the best 
combination of sensitivity and specificity in the detection of this condition.8 Despite 
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this, a multitude of different color Doppler signs have been reported in the recent past 
and it is not entirely certain which sign should be used to diagnose AIP.8-19 The aim 
of this review was to systematically report the predictive accuracy of different Color 
Doppler signs in identifying invasive placental disorders prenatally. 
 
 
Material and methods 
This review was conducted according to a protocol designed a priori and in line with 
recommended procedure for systematic reviews and meta-analyses.20-23 An 
electronic search on Medline, Embase, Cinhal and The Cochrane Library including 
The Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of 
Reviews of Effects (DARE) and The Cochrane Central Register of Controlled Trials 
(CENTRAL) was performed on the 27 March 2016, utilizing combinations of the 
relevant medical subject heading (MeSH) terms, keywords and word variants for 
‘placenta accreta, ‘placenta increta’, ‘placenta percreta’, ‘ultrasound’, ‘invasive 
placenta’ and ‘Color Doppler’, ‘invasive placenta’ and ‘infiltrative placenta. The search 
and selection criteria were restricted to the English language. Reference lists of 
relevant articles and reviews were hand-searched for additional reports (Appendix 
Table 1). 
 
Study selection 
Studies were assessed according to the following criteria: population, outcome, 
prenatal diagnosis of invasive placenta by Doppler ultrasound and study design. For 
the purpose of this study, AIP was defined based on histopathological diagnosis of 
trophoblastic invasion through the myometrium or clinical assessment of abnormal 
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adherence/evidence of gross placental invasion at the time of surgery in the absence 
of histo-pathological evidence.  
The Color Doppler signs explored in this systematic review were classified according 
their location within the uterine-placenta complex. Many analogous definitions of the 
Doppler signs were found in the papers included. For that reason, in order to combine 
data from different studies, the Doppler signs most commonly reported were grouped 
as follow: 
• Placental lacunae – encompassing the following definitions: large linear 
lacunae with low velocities flow, diffuse or focal lacunar flow pattern, vascular lakes 
with turbulent flow, vascular lakes with turbulent flow with high velocity (PSV > 15 
cm/s), dilated vascular channels with diffuse lacunar flow; 
• Uterine serosa-bladder interface – encompassing the following definitions: 
hyper-vascularity/abnormal vascularity of serosa–bladder interface, defined as the 
presence of either an hyper vascularity of the serosa–bladder interface, vessels 
extending from the placenta to the bladder, vessels crossing the interface disruption 
site; 
• Sub-placental zone – encompassing the following definitions: increased sub-
placental vascularity in the retro-placental zone, markedly dilated vessels over 
peripheral sub-placental zone, prominence of sub-placental venous complexes, loss 
of sub-placental Doppler signal, absence of sub-placental vascular signals in the areas 
lacking the peripheral sub-placental hypoechoic zone or vessels bridging the placenta 
and the uterine margin, dilated peripheral sub-placental vascular channels with 
pulsatile venous type flow over the cervix; 
• 3D power Doppler signs - encompassing the following definitions: hyper-
vascularity of the bladder serosa interface in basal, coronal and axial view, irregular 
 32 
intra-placental vascularization with tortuous confluent vessels across placental width, 
inseparable cotyledonal and intervillous circulations. 
 
A detailed individual description of the different Color Doppler signs present in the 
studies included in this systematic review is reported in Appendix Table 2. 
In cases where the overall performance of Color Doppler and the number of imaging 
criteria used to diagnose AIP were not stated, the sign showing the best predictive 
value was used as a surrogate of the final diagnosis. Prospective and retrospective 
cohorts, case-control studies, case reports and case series were analyzed. Only 
studies reporting a prospective diagnosis of invasive placentation and/or the 
evaluation of the single Color Doppler signs and studies for which the value of true 
positive, false positive, true negative and false negative were available were included 
in the final analysis. Opinions and studies carried out only in the first trimester of 
pregnancy were excluded. Case reports and case series with fewer than five cases 
were also excluded in order to avoid publication bias. Studies published before 2000 
were not considered for the analysis; technical advances in ultrasound equipment has 
led to a profound change in imaging processing thus we decided to consider a 
relatively small time window in order to uniform the appearance of the explored signs; 
furthermore, imaging of placental invasive disorders is a relatively recent issue and 
only in the last decade maternal and fetal medicine specialist are becoming confident 
with the detection of these conditions.  
 
Data extraction 
Two reviewers (MM, FD) independently extracted data. Inconsistencies were 
discussed by the reviewers and consensus reached. For those articles in which 
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targeted information was not reported but the methodology was such that the 
information might have been recorded initially, the authors were contacted requesting 
the data.  
 
Quality assessment  
Quality of studies was assessed by using the revised tool for the quality assessment 
of diagnostic accuracy studies (QUADAS-2) tool. Each item scored a ‘‘yes’’, ‘‘no’’, or 
‘‘unclear’’ if there is not sufficient information to make an accurate judgment.24 
 
Statistical analysis 
Summary estimates of sensitivity, specificity, positive and negative likelihood ratios 
(LR+ and LR-) and diagnostic odds ratio (DOR) for the overall predictive accuracy of 
colour Doppler ultrasound overall and by Doppler sign location (Placental lacunar flow 
and Uterine-bladder interface) were computed using the hierarchical summary 
receiver operating characteristic (HSROC) model.25 Rutter and Gatsonis HSROC 
parameterization was used because it models functions of sensitivity and specificity to 
define a summary ROC curve, and its hierarchical modelling strategy can be used for 
comparisons of test accuracy when there is variability in threshold between studies.26 
However, when the number of studies is small, the uncertainty associated with the 
estimation of the shape parameter could be very high, and models may fail to 
converge. Thus, for all meta-analyses in which less than four study estimates could 
be pooled, the DerSimonian-Laird random-effect model was used. The DOR is defined 
as the ratio of the odds of the test being positive if the subject has a disease, relative 
to the odds of the test being positive if the subject does not have the disease 
(PLR/NLR).27 Potential publication bias was formally assessed through Egger's 
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regression asymmetry test and Begg's adjusted rank correlation test. Following 
specific indications for meta-analyses of diagnostic accuracy, we correlated individual 
study sample sizes with both sensitivity and specificity as measures of test 
accuracy.28 Only the meta-analyses with more than 5 studies could be assessed, 
because both tests are unreliable when the number of primary studies is small.26 
Meta-Disc 1.429 and Stata command metandi (Stata Corp. College Station) were used 
to analyze the data. 
 
Results 
General characteristics of the studies 
The search yielded 597 possible citations; of these, 540 were excluded by reviewing 
the title or the abstract. Of the remaining 57 full-text manuscripts that were retrieved, 
46 studies were excluded because they did not meet the inclusion criteria (Appendix 
Table 3), thus 11 studies were finally included in the review.9-19 These 11 studies 
included 891 pregnancies at risk for AIP. A summary of the identified studies is shown 
in Table 1; Appendix Table 2 shows the definition of the individual Colour Doppler 
signs reported in the studies included in this systematic review; a large heterogeneity 
in the description of the signs is present among the different studies.  
Quality assessment based on QUADAS-2 guidelines was conducted on all 11 studies 
included for systematic review (Figure 2). Most of the studies were of high quality and 
there was a low risk of bias and low level of concern regarding the applicability of the 
studies. However, heterogeneity was found in the definition and description of the 
different colour Doppler signs among the included studies. The general characteristics 
of the included studies are reported in Table 1. As regard for publication bias, neither 
Begg's nor Egger's test showed significant p-values for any of the considered 
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outcomes. Although publication bias does not seem to be significant in the present 
meta-analysis, no method is currently validated to formally assess publication bias in 
meta-analyses of diagnostic tests. 
 
Diagnostic accuracy 
The overall performance of Doppler ultrasound in the antenatal diagnosis of invasive 
placental disorders was as follows: sensitivity, 89.69% (95% CI 76.9-95.8); specificity, 
95.81% (95% CI 80.6-99.2), LR+, 21.41 (95% CI 4.3-105.5), LR-, 0.11 (95% CI 0.04-
0.25) and DOR, 199.03 (95% CI 40.5-978.9). Among the different colour Doppler signs 
both placental lacunar flow and abnormalities of the uterine bladder interface showed 
a good predictive accuracy for invasive placental disorders, while Doppler 
abnormalities in the sub-placental zone was not highly predictive for these conditions 
(Table 2). Only two studies (357 women) from which raw data could be extracted 
explored the diagnostic performance of 3D Power Doppler ultrasound;9,14 3D Power 
Doppler ultrasound showed an overall good predictive accuracy for AIP, although 
significant heterogeneity was found between these two studies.  
 
Discussion 
Comparison with other systematic reviews 
A recent systematic review has shown that ultrasound can reliably detect AIP in a sub-
set of women at risk on the basis of a previous history of caesarean section and 
placenta previa.8 In that study, colour Doppler showed a better diagnostic 
performance than conventional 2D ultrasound. However, the study did not provide the 
predictive accuracy of individual colour Doppler signs.  
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Implication for clinical practice 
The increasing incidence of AIP has led obstetrician to the daily practice of these 
conditions. Previous uterine surgery and placenta previa represent the main risk 
factors for the occurrence of these conditions. The prevalence of AIP is highly variable 
and mostly dependent upon the population analysed and type of invasive placentation 
considered.  A recent systematic review reported a prevalence of 19% in a sub-
population of women with an anterior placenta previa confirmed in the third trimester 
of pregnancy and a previous uterine surgery.8 
This high prevalence questions the fact whether all women with placenta previa 
confirmed in the third trimester and a previous caesarean section should be 
considered virtually affected by AIP until detailed prenatal imaging has ruled out this 
condition.  
 
Main findings 
The findings from this systematic review show that placental lacunar flow and 
abnormalities at the uterine bladder interface have a good predictive accuracy in 
detecting AIP, while Doppler abnormalities in the sub-placental zone does not perform 
well in screening for these conditions. The value of 3D Colour Doppler ultrasound has 
to be further ascertained on the basis that only two publications explored the 
diagnostic performance of this new technique in detecting invasive placentation. 
However, a large heterogeneity was present in the description and definition of the 
individual Doppler signs. 
 
Strengths and limitations 
In the current systematic review we have reported the diagnostic accuracy of different 
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colour Doppler signs in detecting AIP. Strength of this review is that the individual 
rather than the overall diagnostic accuracy of Colour Doppler signs was reported; this 
may help in guiding clinicians when facing women at high risk for the occurrence of 
disorders of invasive placental disorders. Furthermore, the current review showed the 
high variability in the definition of the different ultrasound criteria and the need for a 
standardization of the ultrasound diagnosis of AIP. The heterogeneity in study design, 
populations analysed and reference standards adopted among the different studies 
represents a major weakness of this meta-analysis and several factors such as 
gestational age at assessment, ultrasound setting, type of scan and operator’s 
experience might have influenced the final results. Furthermore, as for several meta-
analyses, the number of included studies was small and some of these studies also 
had a small sample size. In such situations, estimates of the variances of the random 
effects are subject to a high level of uncertainty, and caution is required when 
interpreting the results. A major limitation in the interpretation of our findings is the 
high degree of variability in the definitions of the Doppler signs adopted among the 
available studies. Different authors tend to define similar criteria in different ways. This 
makes a comparison or grouping difficult to be done. Furthermore, many Doppler signs 
were not consistently reported by all the authors, and many other signs were only 
reported in a single study. This background makes the task of assessing the predictive 
accuracy of colour Doppler even harder. 
Prenatal diagnosis of AIP is primary carried out by ultrasound, while MRI is usually 
adopted when ultrasound is not conclusive or to assess the extent of placental 
invasion.30,31 A multitude of gray scale and Colour Doppler ultrasound signs, either 
2D or 3D, has been described in the recent past, however it is not entirely certain yet 
how many and which ultrasound signs show the best combination of sensitivity and 
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specificity. A wide heterogeneity in the diagnostic performance of the same ultrasound 
signs among the different studies was observed in the current review; although the 
adoption of different reference standards for defining AIP, operators’ experience, 
placental position and type of ultrasound scan play an important role in this scenario, 
the heterogeneity in the definition of the individual ultrasound criteria may account for 
these different results. 
In the current review 3D ultrasound apparently shows a better accuracy in detecting 
AIP compared to traditional 2D colour Doppler ultrasound. This result should be 
interpreted with caution especially on the basis of the small number of studies 
included. Furthermore, 3D Colour Doppler is usually adopted only when conventional 
2D colour Doppler has raised the suspicion of invasive placenta, thus the values 
reported in the current review may not reflect the actual diagnostic accuracy of 3D 
Doppler, but its performance only in a highly selected group of patients. Further studies 
assessing the role of 3D Doppler as a primary tool in detecting AIP are needed. 
  
Implication for research 
There is currently strong evidence that prenatal imaging techniques can reliably 
identify AIP in women at risk. Despite this, the large majority of the studies addressing 
the diagnostic ability of ultrasound in detecting invasive placentation differs as regard 
for several technical factors, such as the gestational age at assessment, ultrasound 
machine settings, imaging planes used, number of sonographic signs needed to label 
a scan as suggestive of the disease. Future research should aimed at objectively 
define ultrasound criteria suggestive for the presence of AIP, in order to develop a 
standardized technique for the assessment of women at risk for these conditions. 
An objective description of the signs should be provided as regard for their appearance 
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in relation to the gestational age at scan, type of ultrasound scan (TA and TV), location 
within the utero/placental complex. Furthermore, the reproducibility of the imaging 
signs should also be addressed. 
 
Conclusions 
Colour Doppler ultrasound is highly reliable in detecting AIP in women at risk; despite 
this accuracy a high variability persists in the definition of the sonographic criteria 
suggestive for these disorders. Further studies aiming at objectively defining the 
ultrasound criteria suggestive of AIP are urgently needed in order to standardize the 
diagnosis.  
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Figure 1: Systematic review flow-chart. 
 
 
 
 
 
 
 
 
 
Figure 2: Studies included in the review according to quality assessment of diagnostic 
accuracy studies (QUADAS-2) criteria: proportion of studies with low, high or unclear 
risk of bias (a) or concerns regarding applicability (b).
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Figure 3 
Predictive accuracy of overall Colour Doppler ultrasound in detecting invasive 
placentation disorders based upon hierarchical summary receiver operating 
characteristic (HSROC) model. The curve from HSROC model contains a summary 
operating point (■) representing summarized sensitivity and specificity point estimates 
for individual study estimates; dotted lines: 95% CI.  
 
 
 
 
 
 
  
 45 
Figure 4 
Predictive accuracy of different Colour Doppler signs in detecting MAP Depending on 
the number of studies, computations were based upon DerSimonian-Laird random-
effect (Ψ) or hierarchical summary receiver operating characteristic (HSROC) model 
(W ).The curve from HSROC model contains a summary operating point (■) 
representing summarized sensitivity and specificity point estimates for individual study 
estimates; dotted lines: 95% CI. 
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Table 1: General characteristics of the included studies. 
Author Year 
Study 
design 
Inclusion 
criteria 
USS 
techniques 
Reference 
standard 
Women                                                        
(n) 
Invasive 
placentas 
(n) 
US Doppler signs analysed 
        Cali*9 2013 
Prospe
ctive 
Placenta 
previa and 
previous 
uterine surgery 
TA, TV Pathology 187 41 
1. Placental lacunae with turbulent flow with high velocity (PSV >15 
cm/s).  2. Hypervascularity of uterine serosa-bladder interface. 3. 
(3D) Hypervascularity of uterine serosa-bladder interface. 4.(3D) 
Irregular intraplacental vascularization with tortuous confluent 
vessels across placental width.  
Chalubinski*10 2013 
Retros
pective 
Placenta 
previa +/- 
previous 
cesarean 
section 
TA, TV 
Surgery/ 
pathology 
232 35 1. Placental lacunar flow 
Pecker11 2013 
Prospe
ctive 
Placenta 
previa +/- 
previous 
cesarean 
section 
TA Pathology 40 20 
1. Intraplacental lacunar turbulent flow with high velocity (PSV >15 
cm/s). 2. Abnormal vascularization in the vescico-uterine plane. 
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Mansour*12 2011 
Prospe
ctive 
Placenta 
previa +/- 
previous 
uterine surgery 
TA, TL Surgery 35 15 1. Hypervascularity of the serosa-bladder interface. 
El Behery13 2010 
Prospe
ctive 
Placenta 
previa +/- 
previous 
uterine surgery 
TA, TV 
Surgery/ 
pathology 
35 7 
1. Turbulent or diffuse flow within lacunae.  2. Vessel crossing the 
interface disruption site. 
Shih14 2009 
Prospe
ctive 
Placenta 
previa+/- 
previous 
cesarean 
section 
TA Pathology 170 39 
1. Diffuse or focal lacunar flow. 2. Vascular lakes with turbulent flow 
with high velocity (PSV >15 cm/s) and low resistance waveform. 3. 
Hypervascularity of the serosa-bladder interface. 4. Dilated vessels 
in the subplacental zone. 5. (3D) Intraplacental hypervascularity 
(lateral view). 6. (3D) Inseparable cotyledonal and intervillous 
circulations (lateral view). 7. (3D) Numerous coherent vessels 
involving the whole uterine serosa–bladder junction (basal view). 
Miura15 2008 
Prospe
ctive 
Placenta 
previa+/- 
previous 
cesarean 
Not stated Pathology 12 4 1. Hypervascularity of the serosa-bladder interface. 
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section 
Wong16 2008 
Retros
pective 
Placenta 
previa or 
previous 
cesarean 
section of 
uterine surgery 
or previous 
history of 
invasive 
placentation 
TA, TV 
Surgery/pa
thology 
66 9 
1. Increased subplacental vascularity. 2. Placental lacunar flow. 3. 
hypervascularity of the serosa-bladder interface. 4. Vessels 
extending from the placenta to the baldder. 5. Vessels bridging the 
placenta and the uterine margin. 6. Vessels crossing the interface 
disruption site. 
Japarai17 2007 
Prospe
ctive 
Placenta 
previa and 
previous 
uterine surgery 
TA, TV 
Surgery/pa
thology 
21 7 
1. Dilated vascular channels with diffuse lacunar flow. 2. Interphase 
hypervascularity with abnormal vessels linking the placenta to the 
bladder. 3. Dilated peripheral subplacental vascular channels with 
pulsatile venous type flow over the cervix. 
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Chou18 2000 
Prospe
ctive 
Placenta 
previa+/- 
previous 
cesarean 
section 
TA 
Surgery/ 
pathology 
80 14 
1. Diffuse lacunar flow with high-velocity pulsatile venous-type flow. 
2. Focal lacunar turbulent flow. 3. Interphase hypervascularity with 
abnormal blood vessels linking the placenta to the bladder. 4. 
Dilated peripheral subplacental vascular channels with pulsatile 
venous-type flow over the uterine cervix. 5. Absence of subplacental 
vascular signals in the areas lacking the peripheral subplacental 
hypoechoic zone. 
Twickler19 2000 
Retros
pective 
Placenta 
previa+/- 
previous 
cesarean 
section 
TA 
Surgery/ 
pathology 
215 9 1. Large linear intraplacental lacunae with low velocities flow. 
 
*: additional data provided by the authors 
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Table 2. Summary estimates of sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-) and diagnostic odds ratio 
(DOR) of Doppler ultrasound overall, 3D, and by colour Doppler sign location (Placental lacunar flow, Uterine-bladder interface, and 
sub-placental zone) to predict placental invasion. Depending on the number of studies, computations were based upon DerSimonian-
Laird random-effect (Ψ) or hierarchical summary receiver operating characteristic (HSROC) model (W). 
 N. studies N. accreta / 
Total sample 
Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
DOR 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Doppler (overall) 11 W 169/891 89.69 
(76.9-95.8) 
95.81 
(80.6-99.2) 
199.03  
(40.5-978.9) 
21.41  
(4.3-105.5) 
0.11 
(0.04-0.25) 
Placental lacunar 
flow 
9 W 130/824 74.09 
(64.5-81.8) 
96.55 
(73.3-99.6) 
80.14 
(11.6-554.2) 
21.50 
(2.8-162.4) 
0.27 
(0.20-0.36) 
Uterine-bladder 
interface 
9 W 105/637 70.29 
(35.7-91.0) 
97.59 
(87.2-99.6) 
95.90 
(12.0-768.5) 
29.19 
(5.3-162) 
0.30 
(0.11-0.84) 
Sub-placental zone 4 W 20/330 35.80 
(14.9-63.9) 
96.21 
(54.4-99.8) 
14.14 
(0.8-262.9) 
9.44 
(0.6-156.3) 
0.67 
(0.45-0.99) 
3D Doppler  2 Ψ 76/357 95.00 
(87.7-98.6) 
93.14 
(89.5-95.8) 
1020.81 
(132.7-7852.5) 
37.01 
(0.2-7092.6) 
0.06 
(0.01-0.45) 
 
 
Section C – Management (I) 
 
The International Society for Abnormally Invasive Placenta (IS-AIP) 
evidence based guidelines for the management of Abnormally 
Invasive Placenta (AIP) 
 
Collins et al. (submitted, under peer review). 
 
Background 
Abnormally invasive placenta (AIP), also called placenta accreta spectrum 
disorder (PAS), describes the clinical situation where a placenta does not 
separate spontaneously at delivery and cannot be removed without causing 
abnormal and potentially life-threatening bleeding1. There is increasing 
epidemiological evidence demonstrating that the incidence of AIP is rising 
worldwide2. This is most likely due to the rising rates of caesarean delivery, which 
is the greatest single risk factor for AIP in subsequent pregnancies. Optimal 
management requires both accurate antenatal diagnosis and a robust perinatal 
management strategy. However, even with the rising incidence, AIP is still rare 
(0.79-3.11 per 1000 births after prior cesarean)3 and so defining an optimal 
management strategy remains extremely challenging. The literature contains a 
vast number of case reports, case-series and retrospective cohort studies looking 
at multiple management strategies but most studies are small and many are 
methodologically flawed limiting their utility. The situation is made even more 
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difficult by the spectrum of presentations being presented in most studies as a 
binary outcome (‘AIP’ or ‘not AIP’) with varying diagnostic criteria and no 
assessment of severity reported.  
The International Society for Abnormally Invasive Placenta (www.IS-AIP.org) 
evolved from the European Working group on AIP (EW-AIP) and currently 
consists of 42 clinicians, pathologists and basic science researchers from 13 
countries. The IS-AIP’s aim is to optimize the treatment of AIP, and to promote 
research and awareness of the condition internationally. The group has already 
published standardized descriptors to aid in the ultrasound diagnosis of AIP4. 
This paper aims to generate an evidence-based recommendation for the intra-
partum management of AIP using the unique, international composition of the IS-
AIP to provide expert consensus agreement where the evidence identified is 
weak, flawed or absent. 
 
Materials and Methods  
The questions agreed by the IS-AIP membership to be pertinent to the 
management of AIP were framed and agreed on by ‘round table consensus’ at 
an IS-AIP meeting in Prague (October 2016). The search and assessment of the 
published evidence was then undertaken by an individual IS-AIP member 
according to a predefined pro forma (Supplementary material 1). In brief, this 
involved undertaking a full ‘systematic review’ process for each topic including 
formulating an appropriate question specific to AIP using the PICO framework5 
and searching all relevant medical databases (PubMed, EMBASE etc.) and, 
where appropriate, some non-medical databases (e.g. Google). All searches for 
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the 21 different topics were undertaken at various points during 2017. Full text 
versions of all potential papers were then obtained, assessed for relevance and 
critically appraised using the levels of evidence provided by the Centre for 
Evidence Based Medicine6.  
All the completed pro formas detailing the search strategy, results and critical 
analysis for each topic were then sent to the entire membership for consideration. 
Where potential issues were identified (e.g. problems with search terms or the 
studies identified), a second IS-AIP member repeated the process to ensure no 
evidence had been missed. A few topics which revealed little high-quality 
evidence during the original 2017 search were searched again in 2018 to ensure 
no further evidence had been published. The results for each topic were then 
discussed by the membership at an IS-AIP meeting or using web conferencing 
and agreement was reached on the formal IS-AIP recommendation according to 
the level of evidence available. Where no evidence was found, the IS-AIP 
recommendation was generated by expert consensus after discussion. 
 
Results  
What constitutes ‘expertise’ in management of AIP and/or defines a ‘Center 
of Excellence’? 
Evidence for what constitutes an ‘expert’ in the management of AIP is missing 
from the literature despite opening the search strategy to non-medical databases. 
Therefore, the IS-AIP recommendation is based on a consensus opinion (level 5 
evidence) and is: 
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An expert is a person with significant experience in AIP and a high level of 
knowledge and/or skills relating to the condition (Grade D recommendation).  
Whilst there are multiple retrospective cohort studies demonstrating decreased 
maternal morbidity when women are cared for in self-defined ‘Centers of 
Excellence’7-10 there was no definitive evidence for what should constitute such 
a ‘Center of Excellence’. Therefore, the IS-AIP recommendation is based on a 
consensus opinion (level 5 evidence;) and is summarized in Table 1.  
This recommendation was reached independently of the recently published FIGO 
consensus statement11 but is in agreement with it. 
 
Is there a reduction in morbidity if women antenatally diagnosed with AIP 
remain in hospital until delivery? 
There were no studies identified which specifically addressed the question of 
inpatient versus outpatient care for women antenatally diagnosed with AIP. As 
the majority of AIP cases are also placenta previa, an examination of the 
evidence available for placenta previa was also made. There were five 
publications reporting outcomes for expectant outpatient management of women 
with placenta previa (one small RCT12 and four retrospective cohort studies13-
16).  
The oldest publication from 198415 presented data from a retrospective cohort 
of 38 women. The authors suggested significant improvement in neonatal 
morbidity and mortality for women with placenta previa who were managed as 
inpatients. However, there appeared to be significant recruitment bias, with the 
woman managed as outpatients being enrolled at significantly earlier gestations 
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compared to those managed as inpatients (Level 4 evidence). 
A subsequent small RCT by Wing et al12 reported the outcomes for 26 
asymptomatic women with placenta previa managed at home compared with 27 
who were hospitalized (level 2b evidence). The only significantly different 
outcome was length of hospital stay. Three retrospective cohort studies13, 14, 
16 examined the outcomes for a total of 305 women (level 2b evidence) and did 
not demonstrate any significant difference in either maternal or neonatal 
outcomes. All three studies concluded that in selected women with asymptomatic 
placenta previa outpatient management was both safe and cost effective. 
However, these were all retrospective cohort studies and there may have been 
individual circumstances which biased the selection of care settings for the 
women involved. This evidence for outpatient management of placenta previa 
was taken into consideration when reaching the consensus recommendation for 
the management of AIP. 
In conclusion, there is no evidence for antenatal hospitalisation of asymptomatic 
women with antenatally diagnosed AIP, whether it is associated with placenta 
previa or not. Therefore, the IS-AIP recommendation is extrapolated from the 
small RCT for inpatient management of placenta previa12 (level 2b evidence) 
and is as follows: 
Expectant outpatient management of women with AIP, even in the presence of 
placenta previa, is acceptable treatment, as long as the woman is asymptomatic 
and has been appropriately counselled (Grade C recommendation). However, 
adequate resources must be available to allow rapid return to the hospital (Grade 
D recommendation).  
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Symptomatic women should be cared for according to local protocols and 
expertise (Grade D recommendation). 
 
Is there evidence of reduced morbidity in women antenatally diagnosed 
with AIP if they receive iron supplementation to optimize hemoglobin 
levels? 
There was no evidence available for the benefit of antenatal optimization of 
haemoglobin (Hb) specifically for cases of AIP. A single study nested in a 
community based RCT of treatments for severe anaemia in women from Zanzibar 
was identified which reported that women with Hb of <90g/L at delivery were at 
increased risk of blood loss both at the time of birth and in the immediate 
postpartum period, irrespective of mode of delivery17 (level 1b evidence). This 
study was taken into consideration but it does not answer the original question 
posed therefore, the IS-AIP recommendation is based on a consensus opinion 
(level 5 evidence) and is as follows: 
As soon as women are antenatally diagnosed with AIP they should have their Hb 
level measured. If it is low (<110g/l before 28 weeks’ gestation or <105g/l after 
28 weeks’), appropriate haematinic investigations should be undertaken and if 
indicated, iron supplementation (oral or intravenous) should be given to optimize 
their Hb level before surgery (Grade D recommendation).  
This recommendation was reached independently but is in agreement with the 
UK RCOG prevention and management of postpartum hemorrhage guideline 
(Green-top number 52)18 and the recent FIGO consensus statement11. 
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At what gestation should women with antenatally diagnosed AIP be 
delivered? 
Six studies were found which reported maternal and neonatal outcomes for 
different gestational ages at delivery in women with an antenatal diagnosis of 
AIP8, 19-23. All six were retrospective observational studies (level 4 evidence). 
It was not possible to draw any firm conclusion on the optimal gestational age for 
delivery for woman with AIP, to reduce maternal and neonatal morbidity whilst 
still minimizing the rate of unplanned, emergency delivery. Therefore, although 
these studies were taken into consideration, the IS-AIP recommendation is based 
on a consensus opinion (level 5 evidence) and is as follows: 
The timing of delivery should be tailored to each unique set of circumstances and 
based on the individual woman’s risk of emergent delivery. To reduce the risk of 
neonatal morbidity it is reasonable to continue expectant management until after 
36+0 weeks’ gestation for women with no previous history of pre-term delivery 
(<36+0 weeks) and who are stable with no vaginal bleeding, PPROM, or uterine 
contractions suggestive of pre-term labor.  
In the case of women with history of previous pre-term birth, multiple episodes of 
small amounts of vaginal bleeding, a single episode of a significant amount of 
vaginal bleeding or PPROM, planned delivery at around 34+0 week’s gestation 
should be considered given the significantly increased risk of emergent delivery 
(Grade D recommendation).  
 
Is there evidence of reduced mortality or morbidity in neonates if women, 
with antenatally diagnosed AIP, receive corticosteroids for delivery 
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occurring after 34+0 weeks’ gestation? 
No prospective RCT exists evaluating the influence of AIP per se on neonatal 
respiratory morbidity beside the normal influence of prematurity when delivered 
between 34+0 and 37+0 weeks of gestation. One retrospective case series (level 
4 evidence) of histopathologically diagnosed AIP compared the neonatal 
outcomes between antenatally diagnosed AIP and AIP cases diagnosed 
intrapartum 23. Although there was no significant difference between the 
gestation at delivery (33.9 vs 34.7 weeks; p=0.34) for the two groups, those 
antenatally diagnosed were more likely to have received antenatal steroids (65% 
vs 16%; p<0.001) yet still demonstrated a higher rate of admission to the neonatal 
intensive care unit (86% vs 60%; p=0.005), and longer neonatal hospital stays 
(11 vs 7 days; p=0.006). Interpretation of this dataset is difficult with regard to the 
specific question as there are likely to be considerable confounding factors. 
There was no evidence available that the presence of AIP itself increases 
neonatal respiratory morbidity or mortality if the scheduled delivery takes place 
between 34+0 and 37+0 weeks of gestation. Therefore, the IS-AIP 
recommendation for antenatal glucocorticoid treatment to induce fetal lung 
maturation for a scheduled delivery after 34+0 weeks of gestation is based on 
consensus opinion (level 5 evidence) and is as follows:  
An individualized approach for antenatal steroid administration should be 
employed, based on the current local guidelines for the specific gestation at 
delivery, irrespective of the suspicion or diagnosis of AIP (Grade D 
recommendation).  
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Does routine pre-operative cystoscopy improve the accuracy of pre-
operative diagnosis of AIP and/or reduce maternal morbidity in women with 
antenatally diagnosed AIP? 
No RCTs were found examining the efficacy of pre-operative cystoscopy for the 
management of AIP. One case series presented 12 patients with AIP and gross 
hematuria (level 4 evidence) who underwent pre-operative cystoscopy24. The 
authors reported that the procedure did not establish a preoperative diagnosis in 
any patient and concluded that cystoscopy had minimal diagnostic value.  
The evidence that cystoscopic findings, even in the presence of gross hematuria, 
do not correlate to the level of bladder involvement was taken into account but, 
given the poor quality of this study, the recommendation is also supported by 
consensus opinion (level 5 evidence).  
The IS-AIP does not recommend undertaking routine pre-operative cystoscopy. 
If pre-operative cystoscopy is performed for insertion of ureteric stents, the 
appearance of the bladder should not change the (imaging-based) plan of 
management (Grade D recommendation). 
 
Does routine ureteric stent placement reduce maternal morbidity in cases 
of antenatally diagnosed AIP?  
One retrospective cohort study25 (level 2b evidence), of 57 cases of suspected 
AIP and 19 undiagnosed cases reported on ureteric stenting and unintentional 
urinary tract injury. Ureteric stenting was attempted in 25 of the suspected cases. 
The stent placement was achieved bilaterally in only 68% (17/25) of cases, on 
only one side in 16% (4/25) of cases, and neither side in 16% (4/25). Women with 
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bilateral ureteral stents had a lower incidence of early morbidity compared with 
women without stents (18% (3/17) vs. 55% (22/40), p = 0.018). A non-significant 
reduction in ureteric injury was observed (0 vs. 7%).  
A systematic review of 49 case series and case reports (level 3a evidence), 
including the above cohort study, attempted to examine the efficacy of 
approaches aimed at minimizing urinary tract injuries in AIP26. Of the 292 women 
with AIP, whether ureteric stents were successfully placed or not, was reported 
for 90 cases only. No details were available on the number in whom it was 
attempted but unsuccessful. The risk of urinary tract injury was significantly lower 
in the group with ureteric stents in situ (2/35) compared to those who were known 
not to not have stents (18/55; p=0.01). 
On the basis of this evidence and consensus opinion (level 5 evidence) the IS-
AIP recommendation is: 
Placement of ureteric stents may be beneficial in preventing ureteric injury and 
early morbidity (Grade B recommendation). However, given the potential risks 
associated with stent placement, the evidence is not strong enough to 
recommend routine placement of ureteric stents for all suspected cases of AIP. 
The benefit from ureteric stents is probably limited to cases of percreta with 
significant invasion where hysterectomy is likely to be highly complex (Grade D 
recommendation). 
 
Does routine insertion of prophylactic balloon catheters into the pelvic 
vasculature reduce maternal morbidity in cases of antenatally diagnosed 
AIP?  
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A systematic review has recently been published looking at endovascular 
interventional modalities for hemorrhage control in AIP27. This included both 
prophylactic arterial balloon occlusion and pelvic vasculature embolization. Only 
16 of the 69 included studies were controlled with the remaining being cohort, 
case series or case studies (level 3a). The heterogeneity of the studies was 
reported by the authors to be significant. All grades of AIP 
(accreta/increta/percreta) were grouped together for the meta-analysis with no 
differentiation in severity, with some studies including only balloon occlusion and 
others using vascular embolization. The authors however, concluded that 
“endovascular intervention is effective in controlling hemorrhage in abnormal 
placentation deliveries”. 
One small RCT (level 2b evidence)28 was found that had been included in the 
systematic review27. This randomized 27 women with AIP and showed no 
difference in the number of packed red blood cell (RBC) units transfused for 
women who underwent placement of balloon catheters in the iliac arteries 
compared to those who did not. This RCT however, also reported that 15% of the 
women with balloon catheters experienced an interventional radiology (IR) 
related complication.  
The IS-AIP considered the findings of both these two studies. The RCT is a much 
smaller data set but is more methodologically rigorous (level 2b evidence). The 
systematic review, whilst larger is heterogeneous and may be open to significant 
bias. Therefore, taking into account the quality of the evidence available the IS-
AIP recommendation is as follows: 
The effect of prophylactic arterial balloon catheters on bleeding and morbidity 
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among women with a prenatal diagnosis of AIP has yet to be confirmed. 
Significant adverse events have been reported from this procedure. Larger, 
prospective, appropriately controlled studies are needed to demonstrate both the 
safety and efficacy of prophylactic balloon occlusion. Given this, the IS-AIP 
cannot recommend routine use of prophylactic pelvic arterial balloon catheters 
for all cases of suspected AIP (Grade B recommendation).  
This recommendation was reached independently of the recently published FIGO 
consensus statement11 but is in agreement with it. 
 
Is there an optimal maternal position for surgical delivery of women with 
antenatally diagnosed AIP? 
There are no publications which specifically address the question of maternal 
position for surgery for women with AIP. Therefore, the IS-AIP recommendation 
is based on consensus opinion (level 5 evidence) and is as follows: 
When hysterectomy is either planned or likely, the woman should be placed in a 
position where the vagina is potentially accessible (such as lithotomy or legs 
straight on the operating table but parted) to facilitate manipulation of the cervix, 
if required to assist the hysterectomy. This will also allow easier assessment of 
any blood lost vaginally (Grade D recommendation).  
 
Does routine vertical midline incision instead of using a transverse incision 
reduce maternal morbidity in cases of antenatally diagnosed AIP?  
No studies were found comparing either maternal or fetal outcomes for different 
skin incisions. In the few publications that mention the type of skin incision, 
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vertical midline incision appears to be used most frequently and is often 
anecdotally recommended. Other transverse incisions, such as Pfannenstiel and 
Maylard, have been reported and recommended based on both aesthetic 
considerations and the potential for a reduction in post-surgical complications. 
Given the lack of evidence, the IS-AIP recommendation is based on consensus 
opinion (level 5 evidence) and is as follows: 
There is no evidence of benefit for routine use of a vertical, midline incision for all 
cases of antenatally diagnosed AIP. The decision regarding which type of skin 
incision is used, should be made by the operating team. The location of the 
placenta, degree of invasion suspected, likelihood of intraoperative 
complications, maternal body habitus, gestational age and preference of the 
operating surgeon/obstetrician, should all be taken into consideration (Grade D 
recommendation). 
 
Does making a uterine incision in the upper segment to avoid transecting 
the placenta reduce maternal morbidity in cases of antenatally diagnosed 
AIP?  
One retrospective case series (level 4 evidence)29 reported blood loss after 
transverse fundal uterine incision to avoid the placenta in 34 women with placenta 
previa, 19 of whom had intraoperatively confirmed AIP. The average blood loss 
reported was 1,370g. There was no control group and the severity of AIP was not 
reported, yet the authors conclude that this blood loss “compares favourably with 
the volume lost during a routine transverse lower segment section performed in 
patients without placenta previa or accreta”. It is not possible to draw any firm 
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conclusion from this study therefore the IS-AIP recommendation is based on 
expert consensus (level 5 evidence) and is as follows: 
Avoiding placental transection when making the uterine incision is essential if AIP 
is clearly evident on opening the abdomen, and is reasonable for women with 
antenatally suspected AIP but with no definite evidence seen at laparotomy, even 
if it means making an upper segment or fundal incision, as it is likely to reduce 
maternal blood loss from the placental bed (Grade D recommendation).  
 
Does routine intraoperative ultrasound (US) to map the placental edges 
before uterine incision reduce maternal morbidity in cases of antenatally 
diagnosed AIP?  
Several reports in the literature anecdotally recommend the use of intraoperative 
US usually with the probe directly placed on the uterus protected by a sterile 
cover. There is however, a theoretical risk of introducing infection. No publications 
were found which address either the risks or benefits of intraoperative ultrasound 
scanning for placental localization in women with suspected AIP. One study by 
Al-Khan et al.8 retrospectively analyzed patients before and after an institutional 
protocol for AIP management was introduced. In their protocol, intraoperative US 
for placental localization is performed but the improvement in outcomes cannot 
be directly attributed to any individual measure. Therefore, the IS-AIP 
recommendation is based on a consensus of experts (level 5 evidence) and is as 
follows: 
If the US scan is undertaken in an appropriately sterile manner, the small 
theoretical risk of introducing infection is outweighed by the benefit of ensuring 
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the incision is made away from the placental bed. Therefore, intraoperative US 
of the exposed uterus should be used, where possible, to locate the placental 
edge and assist decision-making regarding the uterine incision site (Grade D 
recommendation). 
 
Does routine prophylactic administration of oxytocin after delivery of the 
baby reduce maternal morbidity in cases of antenatally diagnosed AIP? 
There is evidence for the prophylactic administration of oxytocin after delivery at 
routine caesarean delivery to prevent PPH30. However, the use of routine 
oxytocin at caesarean in cases of antenatally suspected AIP, has not been 
addressed in any study. Therefore, the IS-AIP recommendation is based on a 
consensus of experts (level 5 evidence) and is as follows: 
Prophylactic administration of oxytocin immediately after delivery increases 
contraction of the uterus which could be helpful for the assessment of placental 
separation. If the whole placental bed is abnormally invasive, uterine contraction 
will not result in any placental separation. If, however, the placenta is only partially 
adherent or invasive, uterine contraction may cause some separation leading to 
increased blood loss which could prompt the surgeon to forcibly remove the rest 
of the placenta or perform a more hurried hysterectomy. In light of this risk, the 
IS-AIP recommend that when AIP is suspected antenatally, prophylactic 
uterotonic agents should not be routinely given immediately after delivery of the 
infant. Instead a full assessment should be made in accordance with the 
intraoperative diagnosis recommendations (see next topic). Only if the placenta 
is removed, either fully or partially, or there is already significant bleeding, should 
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uterotonics be given (Grade D recommendation). 
 
Is there an optimal method for intrapartum clinical diagnosis of AIP?  
No evidence was found for which clinical diagnostic method best correlates with 
the gold-standard histopathological diagnosis therefore, the IS-AIP 
recommendation is based on a consensus of experts (level 5 evidence) and is as 
follows: 
The IS-AIP agree with the ACOG recommendation (level 5 evidence) that given 
the high risk of false positive with all methods of antenatal diagnosis there must 
be robust intra-partum evidence that there is actually significant AIP before 
surgical treatment is commenced. Care must be taken however, that major 
hemorrhage is not caused by inappropriate attempts to manually remove an AIP. 
The IS-AIP recommend the following methods for clinically diagnosing AIP: 
At Vaginal delivery 
The diagnosis of AIP should not be made if the placenta spontaneously separates 
and is delivered by maternal effort, controlled cord traction or simple manual 
removal of an already separated placenta, even if there is a subsequent diagnosis 
of retained products of conception (RPOC). For the diagnosis of AIP, a manual 
removal of placenta is required and at the time of manual exploration of the 
uterine cavity, in the opinion of a senior, experienced obstetrician, no plane of 
cleavage can be identified between the placenta and the myometrium. This can 
be for the entire placenta bed or just in ‘focal’ areas.  Major hemorrhage after 
piecemeal removal, removal of a ‘ragged placenta’ or discovery of subsequent 
RPOC is not sufficient to make the diagnosis of AIP (Grade D recommendation). 
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At Laparotomy, at stepwise process should be followed: 
Step 1: On opening the abdomen the external surface of the uterus and the pelvis 
should be thoroughly inspected for frank signs of AIP which include: 
• Uterus over the placental bed appears abnormal (can have a vascular, 
bluish/purple appearance) with obvious distension (a placental ‘bulge’).  
• Placental tissue seen to have invaded through the surface of the uterus. 
This may or may not have penetrated the serosa. NB Care should be taken not 
to confuse this with a uterine ‘window’ which is a uterine scar dehiscence with the 
placenta visible directly underneath it. If it is a ‘window’ the surrounding uterine 
tissue will appear normal. 
• Excessive, abnormal neo-vascularity in the lower segment (particularly 
with vessels running cranio-caudally in the peritoneum). 
If these are clearly seen, AIP can be diagnosed confidently without recourse to 
any further procedures (Grade D recommendation). 
Step 2: If these are not seen, then the uterine incision should be made according 
to the level of suspicion for AIP (see separate topic above). If the incision has 
been placed such that the placenta is undisturbed, then gentle cord traction 
should be attempted. If traction on the umbilical cord causes the uterine wall to 
be visibly pulled inwards in the direction of traction without any separation of the 
placenta (the ‘dimple’ sign) and there is apparent contraction of the uterus 
separate from the placental bed, then AIP can be diagnosed (Grade D 
recommendation). 
Step 3: If AIP has not been diagnosed by the previous 2 steps, then gentle digital 
exploration can be attempted to assess if there is a plane of cleavage (following 
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method for diagnosis of AIP described for vaginal delivery). Care must be taken 
to avoid causing hemorrhage (Grade D recommendation). 
 
In an attempt to assess severity, the IS-AIP use the clinical grading score in Table 
2. This grading scale is also recommended by the recently published FIGO 
guidelines31.  
 
Is expectant management of clinically confirmed AIP effective and does it 
reduce maternal morbidity when compared to surgical treatment options?  
The ‘leaving the placenta in situ’ approach, or expectant management, consists 
of leaving the entire placenta untouched and waiting for its complete resorption. 
Attempting forcible removal significantly increases blood loss, hysterectomy 
rates, infection and disseminated intravascular coagulation32 (level 2b 
evidence).  
Kutuk et al33 recently published a retrospective cohort study comparing women 
undergoing hysterectomy without placental removal (n=20), expectant 
management (n=15), and placental removal with uterus conserving surgery 
(n=11) (level 2b evidence). Two cases of percreta were planned to be 
conservative surgery but management was changed to expectant when the 
surgeons found that the placenta had infiltrated the parametrium and the cervix. 
There was significantly lower blood loss in the expectantly managed group (400 
(250-2500) mL) than in both hysterectomy (2000 (500-3500) mL; p<0.001), and 
conservative surgery groups (3000 (1100-4000) mL; p<0.001). None of the 
expectantly managed women received blood products compared with 
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transfusions of 700 (200–2400) mL packed RBC in the hysterectomy group and 
1200 (400–1800) mL in the conservative surgery group. Uterine preservation 
rates were not significantly different between the expectantly managed women 
and those having conservative surgery (14/15 [93%] vs 33/37 [89%]; P>0.99). 
Most studies use avoidance of hysterectomy as the outcome measure of 
successful expectant management. The single largest case series of expectant 
management published to date is a multicenter retrospective study which 
included 167 cases of AIP in 40 teaching hospitals (level 2b evidence)34. The 
overall success rate of uterine preservation was 78% (95% CI 71–84%), with 
severe maternal morbidity reported in 10 cases (6%). An empty uterus was 
obtained spontaneously in 75% of cases with additional hysteroscopic resection 
and/or curettage performed in 25%. One maternal death occurred as a direct 
result of methotrexate injection into the umbilical cord. Another smaller study of 
36 women managed conservatively reported a success rate of 69%35 (level 2b 
evidence). Three reviews of published case series report success rates of 85% 
36, 58% 37 and 60%38. Care must be taken interpreting this as these are not 
independent reviews, many cases are included in all three studies (level 4 
evidence).  
The IS-AIP recommendation is as follows:  
When expectant management is planned and AIP confirmed at delivery, forced 
manual removal of the placenta should not be attempted (Grade B 
recommendation).  
Expectant management appears to be associated with less blood loss and lower 
transfusion requirements than both hysterectomy and local resection and will be 
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successful for between 60% to 93% of women with the remainder undergoing 
hysterectomy, usually for secondary PPH or infection (Grade B 
recommendation). Therefore, this is an appropriate management strategy for 
women wishing to preserve their fertility and in cases where hysterectomy is 
considered to be at very high risk of surgical complications. If women choose this 
option they must be appropriately counselled including being informed that there 
is a 6% risk of severe maternal morbidity (Grade B recommendation).  
 
If expectant management is undertaken for women with AIP does the use 
of adjuvant therapies such as methotrexate and pelvic arterial embolization 
increase efficacy? 
Methotrexate 
No solid evidence supports the use of methotrexate in cases of AIP left in situ. 
Only case reports and small series with no control groups have been reported 
therefore it is impossible to assess efficacy. Severe adverse effects such as 
pancytopenia and nephrotoxicity have been described with methotrexate34. One 
case of maternal death directly related to methotrexate was reported among the 
21 patients who received methotrexate in the largest retrospective cohort of 167 
women34 (level 2b evidence).  
The IS-AIP recommendation is therefore: 
There is no evidence of significant benefit from the use of methotrexate when the 
placenta left in situ. As there is evidence for potential significant harm, the IS-AIP 
do not recommend the use of methotrexate for conservative management of AIP 
(Grade B recommendation). 
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Pelvic arterial embolization 
A systematic review published in 2015, included seven individual studies 
reporting on 177 cases of uterine artery embolization in women with AIP with 
planned conservative management39 (level 2a evidence). Hysterectomy was 
avoided in 159 of these women (90%). The review did not report maternal 
morbidity other than to say “all patients survived”. 
A retrospective cohort study of 45 patients with AIP compared prophylactic artery 
uterine embolization to no embolization for women undergoing conservative 
management40 (level 2b evidence). No difference was observed in blood loss, 
hysterectomy rates or incidence of massive transfusion. However, one patient in 
the embolization group had uterine necrosis requiring hysterectomy.  
A retrospective cohort of 12 patients having embolization to assist conservative 
management reported uterine necrosis requiring hysterectomy in one women41 
(level 2b evidence). This study was included in the systematic review39. 
The IS-AIP recommendation is therefore: 
There is no evidence for prophylactic uterine artery embolization increasing 
efficacy of conservative management and two cases of uterine necrosis have 
been reported in two cohort studies (level 2b evidence). Therefore, the IS-AIP do 
not recommend prophylactic uterine artery embolization in women undergoing 
conservative management (Grade B recommendation). However, therapeutic 
embolization for postpartum hemorrhage in conservatively managed women may 
avoid hysterectomy (Grade D recommendation). 
 
Does local surgical resection reduce maternal morbidity in women 
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antenatally diagnosed with AIP when compared to other treatment options 
including hysterectomy and conservative management? 
Eleven original publications were found that reported on a variety of local 
resection techniques, seven were retrospective cohort studies, three prospective 
studies and 1 review. Only one retrospective cohort study42 (level 2b evidence), 
compared planned hysterectomy to local resection and found less bleeding in the 
local resection group measured as packed RBC transfusion (1.1 units compared 
with 2.2 units; P<0,05). One retrospective cohort study43 (level 2b evidence), 
compared a peripartum local resection technique known as the ‘Triple-P’ 
procedure to conservative management leaving the placenta partly or entirely in 
the uterus. Blood loss was lower in the ‘Triple-P’ group (1700 ± 950mL vs 2170 
± 246mL) but this difference was not statistically significant (P = 0.445). The need 
for emergency peripartum hysterectomy was significantly lower in women 
undergoing the ‘Triple-P’ procedure than in the control group (0/19 (0.0%) vs 3/11 
(27.3%), P = 0.045).  
Wei et al44 published a retrospective, cohort study of 96 patients with 
histopathologically confirmed AIP who were treated by local resection with (n=45) 
or without (n=51) a Foley catheter tied around the lower uterine segment to 
enhance haemostasis (level 2b evidence). Use of the Foley catheter appeared to 
reduce blood loss and possibly also the hysterectomy rate (0 vs. 3). 
Clausen et al45 published a retrospective consecutive case series of placenta 
percreta treated with either hysterectomy or local resection (level 4 evidence). Of 
the 11 women requesting fertility preservation, nine were successfully treated 
with local resection with a blood loss of 1,300 to 6,000 mL. The eight women 
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undergoing hysterectomy had a blood loss of 450 to 16,000 mL. The difference 
in blood loss between the two treatments, however, does not reflect intention to 
treat. The one woman who had a 16,000mL blood loss had requested fertility 
preservation and local resection was attempted initially followed by a 
hysterectomy as the placenta had invaded into the cervix and parametrium. 
Kutuk et al33 published a retrospective cohort study comparing women 
undergoing hysterectomy without placental removal (n=20), expectant 
management (n=15), and women who underwent placental removal and uterine 
conserving surgery (n=11) (level 2b evidence); see the topic on expectant 
management for further details. 
In all of the other studies the intended surgical procedure was local resection and 
there was no comparator group 46-51. The success rates for avoiding 
hysterectomy ranged between 67% and 100%. 
In 2014 Clausen et al. published a review of 119 patients with placenta percreta 
stratified by mode of management37 (level 4 evidence): 17 cases reported were 
local resection with no secondary hysterectomies; 36 cases were conservatively 
managed, of these 3 underwent a planned delayed hysterectomy and 18 had 
emergency hysterectomies; 66 had primary caesarean hysterectomies. Local 
resection was reported to be associated with a lower rate of complications 
including urinary tract injury, secondary hemorrhage and infection. However, 
there was no information provided regarding how the choice for local resection 
was made. 
The evidence available for the efficacy of local resection is complicated by 
selection bias and poor comparator groups making interpretation of the results 
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difficult. However, the IS-AIP recommendation based on the available evidence 
and supported by consensus opinion, is as follows:  
There is no evidence to demonstrate that routine local resection in all cases of 
AIP reduces maternal morbidity or mortality compared to other treatment 
methods. However, in appropriately selected cases, local resection appears to 
be reasonably successful (level 2b evidence) and may reduce blood loss and 
maternal morbidity compared to hysterectomy (level 2b/4 evidence) and 
requirement for emergency hysterectomy compared with conservative 
management (level 3b evidence). However, there is some evidence to suggest 
that attempting local resection may be detrimental in cases involving invasion into 
the uterine cervix and/or parametrium (level 4 evidence). Therefore, local 
resection should only be considered in selected cases where there is no invasion 
into the parametrium and/or uterine cervix (Grade C recommendation).  
The IS-AIP expert consensus of what constitutes an ‘appropriate case’ for local 
resection is focal disease with an adherent/invasive area which is <50% of the 
anterior surface of the uterus (Grade D recommendation). More evidence is 
required to fully identify which women will most benefit from this management 
strategy (Grade D recommendation).  
 
Does performing a sub-total hysterectomy reduce maternal morbidity in 
women antenatally diagnosed with AIP when compared to total 
hysterectomy? 
Whilst several studies on AIP reported the actual numbers of sub-total and total 
hysterectomy performed in their cohorts, no evidence for the benefit of one type 
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of hysterectomy compared to another was presented. Wright et al52 reported on 
4967 retrospectively collected cases of peripartum hysterectomy performed in the 
USA (level 3b evidence). AIP was the stated indication for 1789 (36%) of these 
hysterectomies. No sub-group analysis of the AIP cases was presented. For the 
overall dataset of all peripartum hysterectomies, total hysterectomy was 
associated with more bladder injuries (10.2% vs. 7.2%, P<0.001), an increased 
number of other operative injuries (10.4% vs. 8.3%, P=0.02), more 
gastrointestinal complications (7.9% vs. 6.3%, P=0.04) and a longer hospital stay 
(P<0.001). Sub-total hysterectomy was associated with more secondary 
operations (5.0% vs. 3.6%, P=0.02), higher rates of transfusions (52.4% vs. 
42.7%, P<0.001) and a higher perioperative maternal death rate (1.4% vs.0.8%, 
P=0.04). 
Knight et al, on behalf of the UK Obstetric surveillance system (UKOSS), 
examined all the peripartum hysterectomies occurring in the UK over a 12 month 
period53 (level 3b evidence). For the 318 hysterectomies performed there were 
no significant differences in outcomes between total and subtotal hysterectomy. 
One hundred and nineteen of the hysterectomies were performed for AIP, these 
were more commonly total hysterectomies but no sub-group analysis between 
the two methods was reported. 
Another six small retrospective studies were identified (level 3b/4 evidence). 
Ogunniyi et al reported 32 cases of peripartum hysterectomy54 and 
demonstrated that sub-total hysterectomy was associated with higher post-
operative morbidity than total (55.6% vs 71.4%; p<0.01). Roopnarinesingh et al. 
reported 52 cases in a single center in Dublin55. They found that total 
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hysterectomy was associated with a significantly higher transfusion rate (12.7 
units vs. 9.4units; P<0.001). Saeed et al reported on 39 cases from a single 
center in Pakistan56 and found that total hysterectomy had a significantly higher 
number of postoperative complications than sub-total. 
D’Arpe et al. reported on 51 cases from a single center in Italy57, Daskalakis et 
al. reported 45 cases from a single center in Athens58and Olamijulo et al reported 
on 34 cases from a single center in Nigeria59. No significant differences in 
morbidity were found in these studies (level 4 evidence). 
No information was available in any study regarding how the decision was made 
regarding the method of hysterectomy. Therefore, the evidence available is highly 
likely to be complicated by considerable selection bias making interpretation of 
these results extremely difficult. Therefore, the IS-AIP recommendation is also 
supported by consensus opinion (level 5 evidence): 
There is no evidence to demonstrate that routine sub-total hysterectomy in all 
cases of AIP reduces maternal morbidity or mortality compared to total 
hysterectomy, in fact the largest study published suggested that sub-total might 
be associated with a higher maternal mortality rate (level 3b evidence).  
The type of hysterectomy performed therefore, should be individualized on a case 
by case basis, taking into account the site and degree of invasion both suspected 
antenatally and found at laparotomy, and the preference of the operating team 
(Grade C recommendation). In cases with cervical invasion total hysterectomy 
should be performed (Grade D recommendation).  
 
Does performing a planned delayed hysterectomy reduce maternal 
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morbidity in women antenatally diagnosed with AIP when compared to 
hysterectomy at the time of caesarean? 
A planned delayed hysterectomy involves leaving the placenta untouched in the 
uterus at the time of delivery with the intention of performing a hysterectomy at a 
later date for example 5 to 6 weeks after the caesarean delivery. Only one 
retrospective study was identified that attempted to compare planned delayed 
hysterectomy with immediate hysterectomy60. However, all the immediate 
hysterectomy cases presented as emergencies without antenatal diagnosis and 
with signs of shock from hemorrhage. The delayed cases were all antenatally 
diagnosed and underwent delivery in a haemodynamically stable condition (level 
4 evidence). 
This study was taken into consideration but as it is methodologically flawed, the 
IS-AIP recommendation is based on a consensus opinion (level 5 evidence) and 
is as follows: 
Given the evidence for the success of expectant management for AIP, the IS-AIP 
recommend that the surgical choice should be between immediate surgical 
management (hysterectomy or local resection) and expectant management. 
There is no evidence of benefit of planned delayed hysterectomy, and the 
potential complications of performing a second intentional surgical procedure in 
a stable patient, outweigh the benefits (Grade D recommendation). 
 
What are the most effective intra-operative measures to treat life-
threatening massive hemorrhage in women with AIP should it occur at the 
time of delivery? 
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We found no RCTs providing direct comparison of different intraoperative 
strategies to reduce blood loss in the event of massive life-threatening 
hemorrhage. 
Pharmacological treatments 
There were no publications that specifically addressed the question of the 
effectiveness of uterotonics or hemostatic/pro-coagulant agents as life-saving 
measures to treat massive hemorrhage directly attributable to AIP. Therefore, the 
IS-AIP recommendation is based on consensus opinion (level 5 evidence) and is 
as follows:  
Uterotonics should be considered in accordance with local protocols whenever 
massive uterine bleeding occurs until either hemostasis is achieved or the uterus 
is removed. Hemostatic/pro-coagulant agents can also be used in accordance 
with local protocols where the surgeon believes they will be of benefit (Grade D 
recommendation). 
The benefit of early administration of tranexamic acid in reducing maternal 
mortality has been proven in a large multi-centre RCT of PPH from all causes, 
including AIP61(level 1b evidence). Therefore, the IS-AIP recommendation for its 
use is as follows:  
Tranexamic acid should be administered whenever massive hemorrhage occurs, 
preferably as soon as possible after onset of significant bleeding (Grade A 
recommendation).  
 
Surgical treatments 
Internal Iliac Artery Ligation 
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Four retrospective studies were identified reporting a total of 105 cases of internal 
iliac artery ligation (IIAL) performed to reduce hemorrhage at deliveries 
complicated by AIP62-65. Three of these were retrospective cases series of 
women undergoing IIAL with no comparator group (level 4 evidence)62, 63, 65 
and one was a retrospective cohort study comparing outcomes for women with 
AIP treated with or without IIAL, at the time of delivery (level 4 evidence)64. The 
authors concluded that IIAL did not contribute to a reduction in blood loss 
however, as the indication for undertaking IIAL was not described, this study is 
highly likely to be confounded by selection bias. Consequently, it was not possible 
to appropriately evaluate the efficacy of IIAL for reducing blood loss.  
Uterine devascularization 
One retrospective study from Verspyck et al66 reported immediate and long-term 
outcomes in six women undergoing surgical uterine devascularization at the time 
of caesarean followed by conservative management of their AIP.No conclusion 
can be drawn from this regarding the efficiency of the technique for hemorrhage 
control but the study demonstrated that uterine devascularization appears to be 
a reasonably safe technique as long as it is not associated with ovarian artery 
ligation. 
Uterine compression sutures 
Compression sutures after extirpation of placenta were reported in three 
retrospective studies67-69 including a total of 47 women. Shahin et al reported 
26 cases of had bilateral uterine artery ligation followed by insertion of a B-Lynch 
suture for major hemorrhage from AIP (level 4 evidence)67. Two of the 26 women 
died. Shazly et al reported a similar case series of seven women with hemorrhage 
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from AIP who underwent bilateral uterine artery ligation and then multiple 
compression suturing68. The authors reported that the procedure was 
successful. For both these studies it is impossible to assess the efficacy of 
compression sutures alone as the treatment also involved arterial ligation. The 
absence of a control group makes it impossible to assess the efficiency of this 
technique to reduce blood loss. Hwu et al reported a case series of 14 women 
who had a vertical compression suture involving both the anterior and posterior 
uterine walls to control bleeding from the placental bed69 (level 4 evidence). One 
of these women was diagnosed with AIP. Again, there was no control group 
making assessment of efficacy in reducing blood loss impossible.  
Balloon tamponade 
One retrospective study70 compared first-line hysterectomy (17 women) and 
balloon tamponade (19 women). Women who were assessed to have >50% 
invasion of the axial plane of the uterus were treated with immediate 
hysterectomy. The remainder had a balloon tamponade after extirpation of 
placenta with or without extra square compression sutures to the placental bed. 
Blood loss and transfusion amounts were significantly lower in the tamponade 
group (p<0.05) however the selection criteria used brings into question the 
appropriateness of the two groups. Also, it was not clear if the tamponade was 
used to prevent or treat hemorrhage. Three retrospective studies looking at 
treatment for PPH have also reported that the presence of an AIP is associated 
with a higher failure rate of balloon tamponade71-73. 
Pelvic Tamponade 
A variety of techniques have been described for pelvic tamponade in the case of 
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persistent bleeding post-hysterectomy. Ghourab et al74 described five cases of 
pelvic packing with 10-12 dry abdominal swabs. Dildy et al75 described a case 
series spanning 38 years of pelvic packing using a variety of materials, including 
pillow cases, gauze sheets, plastic X-ray cassette drapes and orthopedic 
stockings, filled with gauze rolls. Charoenkwan et al76 reported a case series of 
three woman treated with pelvic tamponade using a large volume Bakri balloon. 
There were no maternal deaths in any of the three reports. No comment can be 
made on which technique provides the most effective tamponade.  
In light of the quality and potentially conflicting evidence available, the IS-AIP 
recommendations for the surgical procedures to be used in case of massive 
hemorrhage are mostly based on a consensus of experts (level 5 evidence) and 
are as follows:  
If the woman is stable, the bleeding is not imminently life-threatening and a 
conservative approach was planned (either for maternal request or if 
hysterectomy is anticipated to be at very high risk of surgical complications), 
surgical uterine conserving procedures should be attempted before resorting to 
hysterectomy. The simplest techniques with the lowest complications should be 
performed first.  
If the placenta has been removed, intra-uterine tamponade (e.g. balloon 
tamponade) should be the first line management. If this fails, or the placenta 
remains in situ, uterine devascularisation, with or without uterine compressive 
sutures, should be tried next. Internal iliac artery ligation has the highest risk of 
post-operative complications and therefore should only be performed if the 
previous steps have failed to control the bleeding.  
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If the woman is unstable or the bleeding is life-threatening, treatment must be 
focussed on the source of the blood loss, this will most often be the placental bed, 
so emergency hysterectomy should be performed as rapidly as possible. 
Vascular compression (common iliac arteries or aorta) can be used as a 
temporary measure to gain time to resuscitate the woman and complete definitive 
treatment.  
In case of persistent pelvic bleeding following hysterectomy, internal iliac artery 
ligation and/or pelvic tamponade should be considered. Pelvic tamponade should 
be performed with appropriate, sterile equipment such as large abdominal swabs 
and broad-spectrum antibiotics given whilst they remain in situ (Grade D 
recommendation). 
 
What is the likelihood of a further pregnancy for women who have had an 
AIP and successful uterine conservation? 
There are case reports77-81 (level 4 evidence), case series46, 68, 82, 83 (level 
4 evidence), case-controlled84 (level 3b evidence) and cohort studies85-89 (level 
2b evidence) which clearly demonstrate preservation of fertility after successful 
conservative management of AIP. There are however, no prospective or 
randomized studies.  
The largest cohort of 131 women who had successful conservative management 
of AIP reported that 27 women expressed a desire for a subsequent pregnancy. 
Of these, 24 women (89%) had 34 spontaneously conceived pregnancies 87. 
Another retrospective observational study assessed 46 women who had 
successful conservative management of AIP88, 12 (86%) of the 14 patients 
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desiring another pregnancy achieved a total of 15 pregnancies. The only other 
cohort study presenting outcomes for women desiring a subsequent pregnancy, 
reported five out of six women (83%) achieved a successful pregnancy85. These 
studies included women who had received a multitude of additional treatments 
including administration of methotrexate, embolization of uterine arteries, pelvic 
arterial ligation, hysteroscopic resection of retained tissues and segmental 
excision of the uterus. No study addressed the effect that these different 
management strategies had on fertility preservation or what degree of placental 
adherence/invasion each woman had prior to conservative management. 
Two of the cohort studies also examined the recurrence rates for AIP. In the 
largest study87, AIP recurred in 6 (29%) of the 21 pregnancies which continued 
beyond 34 weeks’ gestation and was associated with placenta previa in 4 cases. 
The other study reported that of the nine patients who delivered after 35 weeks’ 
gestation, two had recurrence of placenta accreta (22%)88.   
There is considerable evidence demonstrating that women who have successful 
conservative management of AIP may go on to have a successful future 
pregnancy. What remains unclear is what effect different methods used for 
conservative management, such as arterial embolization or uterine resection, 
have on fertility rates and what is impact the original degree of adherence or 
invasion. The IS-AIP recommend that: 
Women wishing to preserve their fertility are counselled that this is possible 
(Grade B recommendation). If conservative management is successful, the 
subsequent pregnancy rate is between 86% and 89% (Grade B 
recommendation). There is no evidence regarding the association of AIP degree 
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(accreta/increta/percreta) or methods used for conservative management, and 
successful preservation of fertility.  
Women wishing for fertility preservation should be managed by a team with 
appropriate resources and experience in conservative management according to 
that team’s local protocols (Grade D recommendation). These women should be 
counselled that their risk of AIP in a subsequent pregnancy is between 22 and 
29% (Grade B recommendation).  
 
Discussion 
The paucity of robust evidence for the optimal management of this difficult and 
dangerous condition highlights the urgent need for large, multi-center 
collaborations. However, until the international community comes to an 
agreement on robust clinical definitions, diagnostic criteria and stratification of 
severity for AIP this problem will persist. 
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Section C – Management (II) 
 
Fetal and maternal outcomes of women with antenatal suspected 
abnormally invasive placenta according to gestational age at delivery 
before and after 36 weeks of gestation. 
 
Morlando M. et al. (submitted, under peer review). 
 
Background 
Placenta accreta is a complication of pregnancy characterized by an abnormal 
adherence of the placenta to the uterine wall, secondary to a defect in the decidua 
basalis (1). When the placenta invades the myometrium, the term placenta 
increta is used, whereas placenta percreta refers to a placenta that has invaded 
through the myometrium and serosa, sometimes into adjacent organs. The term 
abnormally invasive placenta (AIP) is often used to describe all of these 
conditions. The reported incidence of abnormal placentation is highly variable, 
ranging from 1:93,000 to 1:111 pregnancies (2) The incidence of abnormal 
placentation is increasing, most likely related to increasing rate of cesarean 
delivery, one of the most important risk factor for AIP (3,4). The optimal 
gestational age at delivery for stable women with suspected AIP is still subject of 
debate (5-10). Choosing the timing of delivery is critical in terms of limiting both 
maternal and neonatal risk. Several studies have suggested the benefits of 
planned delivery in the reduction of maternal morbidity. An early delivery can be 
beneficial as it allows to arrange a multidisciplinary team and to avoid an 
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emergency delivery because of bleeding or labour. In addition to this, the difficulty 
of performing a caesarean hysterectomy in the presence of invasive placentation 
can be higher with advancing gestational age. However, as scheduled delivery 
often means delivery of a premature infant, all the risks related to iatrogenic 
prematurity must be taken into account. The American College of Obstetricians 
and Gynecologists (ACOG) recommends that the timing of delivery should be 
individualized but also that combined maternal and neonatal outcomes are 
optimized in stable patients with delivery at 34-35 weeks without amniocentesis 
(7). The Society for Maternal-Fetal Medicine (SMFM) also emphasize that 
delivery should be individualized due to the lack of randomized trial and of large 
observational studies (8). On the other side, the Royal College of Obstetricians 
and Gynaecologists (RCOG) recommends delivery for asymptomatic and stable 
women at 35+0 to 36+6 (9). The aim of this study is to compare maternal and 
fetal outcomes of women with confirmed AIP delivered before and after 36 weeks 
of gestation. 
 
Material and methods 
This was a prospective cohort study. All consecutive pregnancies at risk of AIP 
because of persistent placenta previa in the setting of prior cesarean delivery who 
delivered at the University of Naples Federico II (Naples, Italy) from January 2006 
to September 2018 were collected prospectively in a dedicated database. For this 
study, pregnancies with different degrees of invasive placentation, diagnosis of 
accreta, increta, or percreta were considered under the umbrella term of AIP. All 
women with placenta previa identified in the second trimester had a follow-up 
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ultrasound at 32-34 weeks. Only those with prior cesarean delivery in whom the 
placenta reached the level of the internal cervical os at the last ultrasound 
examination in the third trimester were considered as women with persistent 
placenta previa in the setting of prior cesarean delivery and therefore at risk of 
AIP. All women underwent transvaginal ultrasound exam. In most cases prenatal 
magnetic resonance imaging was requested to better define the risk of AIP (MRI). 
Women were considered with suspected AIP in case of diagnosis of AIP using 
prenatal MRI (11), or transvaginal ultrasound (12). Women were included only if 
AIP was confirmed either by intraoperative confirmation of by histopathology 
report on a hysterectomy specimen. Ultrasound diagnosis of AIP was made by 
using the standardized ultrasound descriptors for AIP by the European Working 
Group on Abnormally Invasive Placenta (EW-AIP), of which our of the center 
(University of Naples Federico II) is part of (12). The timing of delivery was 
defined according to the individual patient risk of based on anamnestic data, 
ultrasound and MRI signs. Reasons for earlier delivery included history of vaginal 
bleeding and spontaneous onset of labor. Cesarean delivery was planned without 
any attempt to remove the placenta. In cases with macroscopic evidence of 
uterine infiltration at the abdominal entry a cesarean hysterectomy was instantly 
performed. In all other cases hysterectomy was performed when no evidence of 
placental detachment, or heavy continued bleeding from the implantation site of 
a well-contracted uterus after difficult removal of the placenta were noticed. 
Maternal baseline characteristics examined were: maternal age, body mass 
index (BMI), smoke, number of prior cesarean deliveries, number of prior uterine 
curettages. Maternal outcome measures included: the overall length of stay, the 
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post-operative length of stay, the haemoglobin loss after caesarean 
section/hysterectomy, the need for blood transfusions, the total amount of blood 
and blood products transfused, the occurrence of any post-operative 
complication, the classification of the degree of AIP.  
Neonatal outcomes measures included: birthweight, Apgar score at 1 and 5 
minutes, umbilical cord pH, admission to neonatal intensive care unit (NICU), 
antenatal administration of corticosteroids (CCS). Outcomes were compared in 
cohort of women who were delivered before and after 36+0 weeks of gestation.  
 
Statistical analysis 
Statistical analysis was performed using Statistical Package for Social Sciences 
(SPSS) v. 20.0 (IBM Inc., Armonk, NY, USA). Data are shown as means ± 
standard deviation (SD), or as number (percentage). Univariate comparisons of 
dichotomous data were performed with the use of the chi-square or Fisher exact 
test. Comparisons between groups were performed with the use of the T-test for 
continuous variables. Logistic regression, presented as unadjusted odds ratio 
(crude OR) or adjusted odds ratio (aOR) with the 95% of confidence interval (CI) 
was performed. We calculated two sided p-values. A p-value <0.05 was 
considered to indicate statistical significance. 
 
Results 
60 women were included in the present study. In 57 women (95%) AIP was 
suspected on the basis of the ultrasound examination. MRI was performed in 47 
women (78%) and the presence of AIP signs was confirmed in 24 (53%) cases. 
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Only one woman with negative ultrasound was classified as being at high risk for 
AIP following the MRI. Two women with no antenatal suspicion of AIP, were 
included in the present study as they showed intraoperative findings of AIP at the 
time of delivery. On the basis of anamnestic data, ultrasound and MRI, 32 women 
(53%) were delivered before 36+0 weeks of gestation, while 28 (47%) were 
delivered at later gestations. Diagnosis was confirmed by intraoperative findings 
alone in 16 (27%) cases and by intraoperative findings and histopathology exam 
in 44 (73%) cases. All the women included in the present study underwent 
hysterectomy at the time of delivery, due to macroscopic evidence of uterine 
infiltration at the abdominal entry, no evidence of placental detachment, or 
massive bleeding. Table 1 shows the characteristics of the women delivered 
before and after 36+0 weeks of gestation. The two groups were similar in terms 
of maternal demographic characteristics, except for the number of prior 
caesarean sections, which was higher in the group of women who were delivered 
earlier (<36 weeks group) compared to those who were delivered later (≥36 
weeks group). Maternal outcomes were not different among women delivered 
before and after 36 weeks of gestation. There were no differences in post-
operative haemoglobin drop, total and post-operative length of admission, rates 
of women transfused, number of blood products transfused, and in surgical 
complications. There were no differences in the severity of invasion of AIP among 
the 2 groups (table 2). As expected, fetuses delivered <36 weeks had lower 
birthweights (2216 gr vs 2875 gr, p<0.0001) and higher rates of NICU admission 
(50% vs 20%, p=0.032), compared to fetuses delivered at ≥36 weeks. Five 
minutes Apgar scores were also significantly lower in fetuses delivered <36 
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weeks (7,69 vs 8,36, p= 0,029). After adjusting for the number of prior caesarean 
sections, differences in birthweight (aOR 1,86 - 95%CI 1,27 - 2,72) and 5 minutes 
Apgar score (aOR 7,98 - 95%CI 1,20 - 52,95) remained significant among infants 
delivered before and after 36+0 weeks. Umbilical cord pH, 1 minute Apgar scores 
and rates of antenatal corticosteroids administration were not different in the 2 
groups (table 3).  
 
Discussion 
In our population of women with AIP, delivery before 36 weeks is not associated 
with any improvement in maternal outcome in terms of post-operative 
haemoglobin drop, total and post-operative length of admission, need for 
transfusions, number of blood products transfused, and surgical complications. 
On a neonatal perspective, delivery before 36 weeks was associated with lower 
birthweights and lower Apgar scores at 5 minutes.  
 
AIP is a major contributor to maternal morbidity and mortality in many countries 
(13-15). The optimal management regimen has yet to be defined because of the 
paucity of outcome data in the literature and the lack of randomized controlled 
trials. Choosing the timing of delivery is critical in terms of limiting both maternal 
and neonatal risk. An earlier delivery can be beneficial as it allows to arrange a 
multidisciplinary team and to avoid an emergency delivery because of bleeding 
or labour. In addition to this, the difficulty of performing a caesarean hysterectomy 
in the presence of invasive placentation can be higher with advancing gestational 
age. On the other side, a planned delivery at earlier gestations is associated with 
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a rise in all the risks related to iatrogenic prematurity for the neonate (16,17). Our 
data showed that delivery at earlier gestations did not reduce the maternal 
morbidity rate, but it was associated with the delivery of smaller infants with lower 
5 minutes Apgar scores.  
Prematurity is now the second leading cause of death in children under-5 years 
and the single most important direct cause of death in the critical first month of 
life. For the babies who survive, many face a greater risks of serious health 
problems, including cerebral palsy, intellectual impairment, chronic lung disease 
and vision and hearing loss (16). There is a well-recognized gradient of increasing 
risk of mortality and adverse developmental outcomes with decreasing 
gestational age at birth from early term (37–38 weeks) through to the most 
premature survivors. The 5% of those born at 32–36 weeks who survive the 
neonatal period are estimated to have some degree of long-term impairment, but 
this includes 85% of all preterm births, and hence, their contribution to the overall 
morbidity is substantial (17). 
 
There are currently no RCTs or well-controlled observational studies to guide best 
practice in delivery timing of women with a diagnosis of AIP. In cases of 
suspected AIP, where significant blood loss and caesarean hysterectomy is 
anticipated, delivery at between 34 and 35 weeks of gestation has been proposed 
in order to avoid emergency delivery. A 2010 decision analysis supports this 
approach based on the increasing likelihood of emergency delivery as pregnancy 
goes beyond 34 weeks of gestation (6). Some recent retrospective cohort studies 
of women diagnosed prenatally with AIP have indicated that in the absence of 
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risk factors for preterm delivery, it is safe to plan the delivery at 36 weeks of 
gestation. In the first study the authors showed that as gestational age increased, 
the likelihood of vaginal bleeding necessitating urgent delivery decreased, and 
that the estimated blood loss at delivery was not greater among women delivered 
urgently for bleeding compared with those who underwent a scheduled delivery 
(5). This was similar to our findings, as we did not demonstrate a higher rate of 
maternal haemorrhagic complications in women delivered at later gestations. 
Another study of 84 women who had reached 34+0 weeks of gestation with a 
suspected praevia accreta found that those with no risk factors for preterm birth 
are at low risk for an unscheduled delivery prior to 36 weeks of gestation. The 
authors conclude that individual risk stratification is an essential component of 
the delivery planning in order to avoid unnecessary fetal prematurity (18). 
Concerning the fetal outcome in women with AIP the available studies reporting 
on this are limited. One study reporting on fetal oucome at different gestational 
ages at delivery in women with AIP was a retrospective one on 67 pregnancies. 
The incidence of neonatal complications (respiratory distress syndrome, anemia 
of prematurity, transient tachypnea of the newborn, cerebral hemorrhage, 
hypoglycemia, and apnea) was similar at each of the gestational ages 
investigated, with a decline in the rate of complications only at 36 weeks (19). 
These results are similar to our findings of a lower birthweight and lower Apgar 
score at 5 minutes in neonates delivered at < 36 weeks. An additional 
consideration is that the positive predictive value for radiographically-suspected 
AIP is not 100%, therefore unnecessary prematurity based on a false-positive 
diagnosis needs to be considered as a risk of early delivery timing (11). 
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From the analysis of the baseline characteristics of the included women, we found 
that in the <36 weeks group the number of previous sections was significantly 
higher. The number of previous sections is the main risk factor for AIP, and it is 
associated with a significant increase in the risk of AIP in women with a placenta 
previa (4, 20). The anamnestic data of a higher number of previous sections, in 
addition to the ultrasound and MRI features, might have led the attending 
clinicians to classify the women as being at higher risk and therefore to schedule 
them to an earlier delivery. This might have determined a selection of the most 
severe cases in the <36 weeks group. However, the analysis of the degree of 
invasion of AIP, did not show a difference in the rates of the most severe types 
of AIP in the group of women delivered earlier. At the same time, the 
management did not differ among the two groups, as all the included women 
underwent caesarean hysterectomy. 
Our study has several strengths. The main strength is the prospective design, 
covering a wide period of time of 12 years. The population studied is 
characterised by a high caesarean section rate (approximately 60%) with a 
relatively high prevalence of AIP (4). Despite this, we acknowledge that some 
outcomes were underpowered and that the sample size might have limited to 
reach statistical significance for some measures of interest. One more limitation 
of our study is that this a non-randomized comparison.  
This poses the attention on the need for larger multicentre studies on delivery 
timing for AIP, with well-defined protocols for the diagnosis and the management 
of this condition. Future research should also aim at improving the prediction of 
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maternal morbidity, including specific anamnestic and ultrasound findings, which 
may be useful to obtain a delivery planning individualized for the single woman. 
With this purpose our centre is part of the International Society for Abnormally 
Invasive Placenta (IS-AIP - http://www.is-aip.org), aimed at enhancing the 
understanding of the pathophysiology, diagnosis and management of AIP with a 
view of improving outcomes for women worldwide. 
We conclude that delayed delivery at ≥ 36 weeks of gestation for women with AIP 
may help to reduce unnecessary neonatal risks of prematurity and may ensure a 
similar rate of morbidity for the mother. Efforts should be made to restrict the 
earliest AIP deliveries to situations with clear benefits. Further research is needed 
to reach individualized care that will provide the optimal delivery plan for women 
with AIP to optimize both maternal and neonatal outcomes. 
  
 104 
References 
1. Benirschke KKP, Kaufmann P. Pathology of the human placenta, 4th edn. 
New York: Springer, 2000.  
2. Gielchinsky Y, Rojansky W, Fasouliotis SJ, Ezra Y. Placenta accreta: 
summary of 10 years: a survey of 310 cases. Placenta 2002; 23:210–4.  
3. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year 
analysis. Am J Obstet Gynecol. 2005; 192:1458–61.  
4. Morlando M, Sarno L, Napolitano R, Capone A, Tessitore G, Maruotti G 
M, et al. Placenta accreta: incidence and risk factors in an area with a particularly 
high rate of cesarean section. Acta Obstet Gynecol Scand 2013; 92:457–460.  
5. Rac MW, Wells CE, Twickler DM, Moschos E, McIntire DD, Dashe JS. 
Placenta accreta and vaginal bleeding according to gestational age at delivery. 
Obstet Gynecol. 2015 Apr;125(4):808-13 
6. Robinson BK, Grobman WA. Effectiveness of timing strategies for delivery 
of individuals with placenta previa and accreta. Obstet Gynecol. 2010 
Oct;116(4):835-42 
7. Placenta accreta. Committee opinion No 529. American college of 
obstetricians and gynecologist. Obstet Gynecol, 2012; 120:207-11 
8. Publications committee, society for maternal fetal medicine. Belfort MA. 
Placenta accreta. Am J Obstet Gynecol. 2010 Nov;203(5):430-9. Doi: 
10.1016/j.ajog.2010.09.013. 
9. Jauniaux ERM, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, 
Dornan S, Jurkovic D, Kayem G, Kingdom J, Silver R, Sentilhes L on behalf of 
the Royal College of Obstetricians and Gynaecologists. Placenta Praevia and 
Placenta Accreta: Diagnosis and Management. Green-top Guideline No. 27a. 
BJOG 2018 
10. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, 
Moore TR, Resnik R. Effect of predelivery diagnosis in 99 consecutive cases of 
placenta accreta. Obstet Gynecol. 2010 Jan;115(1):65-9. Doi: 
10.1097/AOG.0b013e3181c4f12a.  
11. D’Antonio F, Iacovella C, Palacio-Jaraquemada J et al. Prenatal 
identification of invasive placentation using magnetic resonance imaging: 
 105 
systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2014 
Jul;44(1):8-16. Doi: 10.1002/uog.13327. Epub 2014 Jun 2.  
12. Collins SL, Ashcroft A, Braun T et al. European Working Group on 
Abnormally Invasive Placenta (EW-AIP). Proposal for standardized ultrasound 
descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol, 
2016; 47:271-5. 
13. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. 
The management and outcomes of placenta accreta, increta, and percreta in the 
UK: a population-based descriptive study. BJOG. 2014 Jan;121(1):62-70;  
14. Upson K, Silver RM, Greene R, Lutomski J, Holt VL. Placenta accreta and 
maternal morbidity in the Republic of Ireland, 2005-2010. J Matern Fetal Neonatal 
Med. 2014 Jan;27(1):24-9 
15. Mogos MF, Salemi JL, Ashley M, Whiteman VE, Salihu HM. Recent trends 
in placenta accreta in the United States and its impact on maternal-fetal morbidity 
and heal.thcare-associated costs, 1998-2011. J Matern Fetal Neonatal Med. 
2016;29(7):1077-82. 
16. Howson CP, Kinney MV, McDougall L, Lawn JE; Born Too Soon Preterm 
Birth Action Group. Born too soon: preterm birth matters. Reprod Health. 2013;10 
Suppl 1:S1. 
17. Blencowe H, Lee ACC, Cousens S, Bahalim A, Narwal R, Zhong N, Chou 
D, Say L, Modi N, Katz J, Vos T, Marlow N, Lawn JE. Preterm birth–associated 
neurodevelopmental impairment estimates at regional and global levels for 2010. 
Pediatr Res. 2013 Dec; 74 (Suppl 1): 17–34. 
18. Perlman NC, Little SE, Thomas A, Cantonwine DE, Carusi DA. Patient 
selection for later delivery timing with suspected previa- accreta. Acta Obstet 
Gynecol Scand 2017;96:1021–8. 
19. Al-Khan A, Gupta V, Illsley NP, Mannion C, Koenig C, Bogomol A, Alvarez 
M, Zamudio S. Maternal and fetal outcomes in placenta accreta after institution 
of team-managed care. Reprod Sci. 2014 Jun;21(6):761-71.  
20. Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, et al. 
Maternal morbidity associated with multiple repeat caesarean deliveries. Obstet 
Gynecol. 2006;107:1226–32. 
 106 
TABLE 1: Maternal baseline characteristics. 
Data are presented as number (percentage %), or as mean (standard deviation). 
Boldface data, statistically significant. BMI, body mass index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  < 36 weeks ³ 36 weeks p-value 
Age 34,31 (4,23) 34,43 (5,34) 0,927 
BMI 27,33 (7,60) 29,68 (4,75) 0,153 
Smokers 8 (25%) 7 (25%) 1 
Prior cesarean deliveries 2,34 (1,18) 1,64 (0,68) 0,006 
1 6 (19%) 11 (39%)   
2 17 (53%) 15 (54%)   
3 or more 9 (28%) 2 (7%)   
Prior uterine curettage 0,81 (0,93) 0,80 (1,45) 0,8 
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TABLE 2: Maternal outcomes. 
Data are presented as number (percentage %), or as mean (standard deviation). 
Boldface data, statistically significant. ICU, intensive care unit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  < 36 weeks ≥ 36 weeks p-value 
Overall length of stay (days) 23,19 (15,34) 18 (10,09) 0,133 
Post-operative stay (days) 11,06 (6,07) 10,46 (5,77) 0,698 
Hemoglobin loss 2,94 (1,32) 2,82 (1,79) 0,774 
Need for transfusion 25 (78%) 21 (75%) 1 
Total units transfused 6,31 (7,2) 4,54 (4,82) 0,261 
Red blood cells (units) 3,44 (3,69) 2,79 (2,35) 0,412 
Fresh frozen plasma (units) 2,94 (3,98) 1,75 (2,86) 0,186 
Maternal complications 13 (40%) 9 (32%) 0,595 
Bladder injury 6 (18,8%) 7 (25%)   
Injury to other organs 2 (6,2%) 2 (7,1%)   
ICU admission 7 (21,9%) 4 (13,4%)   
Need for re-intervention  1 (3,1%) 2 (7,1%)   
Other severe complications 2 (6,2%) 3 (10,7%)   
Maternal death 1 (3,1%) 0   
Hystological diagnosis     0,864 
Previa 9 (28%) 7 (25%)   
Accreta 8 (25%) 9 (32,1%)   
Increta 7 (21,9%) 7 (25%)   
Percreta 8 (25%) 5 (17,9%)   
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TABLE 3: Fetal outcomes. 
Data are presented as number (percentage %), or as mean (standard deviation). 
Boldface data, statistically significant. NICU, intensive care unit. CCS, 
corticosteroids. *Adjusted for prior caesarean section (Table 1). 
 
 
 
 
 
 
 
 
 
  < 36 weeks ≥ 36 weeks crude OR (95% CI) aOR (95% CI)* p 
Birthweight 
(decagrams) 22,16 (4,57) 
28,75 
(3,82) 1,69 (1,26 - 2,26) 1,86 (1,27 - 2,72) 0,000 
Apgar 1 min 6,19 (1,89) 6,82 (1,36) 1,28 (0,91 - 1,79) 0,46 (0,18 - 1,16) 0,139 
Apgar 5 min 7,69 (1,49) 8,36 (0,73) 2,06 (1,05 - 4,07) 7,98 (1,20 - 52,95) 0,029 
PH 7,33 (0,04) 7,33 (0,05) 0,00 (0,00 - .) 0,00 (0,00 - .) 0,568 
NICU 16 (50%) 6 (20%) 0,27 (0,09 - 0,85) 1,19 (0,15 - 9,35) 0,032 
Antenatal CCS 26 (81%) 20 (71%) 0,58 (0,17 - 1,93) 0,44 (0,05 - 3,64) 0,54 
